

UNIHEALTH CONSULTANCY LIMITED

8th ANNUAL RESTATED CONSOLIDATED ACCOUNTS

FOR THE YEAR ENDED

31ST March 2023

*Registered Office
H-13/14, 9th Floor,
Everest, 156, Tardeo Road,
Mumbai-400 034*

*Auditors
G P Kapadia and Co.
Chartered Accountants
Hamam House,
Ambalal Doshi Marg
Fort, Mumbai-400 001*

**INDEPENDENT AUDITOR'S EXAMINATION REPORT ON RESTATED
CONSOLIDATED FINANCIAL INFORMATION**

To,
The Board of Directors
Unihealth Consultancy Limited
(Formerly known as Unihealth Consultancy Private Limited)

Dear Sir,

1. We have examined the Restated Consolidated Financial Information of Unihealth Consultancy Limited (formerly known as Unihealth Consultancy Private Limited) (hereunder referred to "the Company", "Issuer") and its subsidiaries namely Bio Health Limited, Aryavarta FZE, Unihealth Tanzania Limited and Unihealth Pharmaceuticals Private Limited (acquired w.e.f March 15, 2023)(the Company and its subsidiaries together referred to as the "Group"), its joint ventures namely Victoria Hospitals Limited and UMC Global Health Limited and its associates namely Unihealth Uganda Limited, comprising the Restated Consolidated Statement of Assets and Liabilities as at March 31, 2023, March 31, 2022 and March 31, 2021, the Restated Consolidated Statement of Profit and Loss, the Restated Consolidated Cash Flow Statement for the Period ended on March 31, 2023, March 31, 2022 and March 31, 2021, the Significant Accounting Policies and Notes to the Restated Consolidated Financial Information and other explanatory Information as forming part of these Restated Consolidated Financial Information (Collectively hereinafter referred as "Restated Consolidated Financial Information" or "Restated Consolidated Financial Statement") as approved by the Board of Directors in their meeting held on August 21, 2023 for the purpose of inclusion in the Red Herring Prospectus (RHP), prepared by the Company in connection with its proposed SME Initial Public Offer of Equity Shares (SME IPO) and prepared in terms of the requirement of:-
 - a) Section 26 of Part I of Chapter III of the Companies Act, 2013 as amended (the "Act");
 - b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 ("ICDR Regulations") as amended (ICDR Regulations"); and
 - c) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India as amended from time to time. ("The Guidance Note")
2. The Company's Board of Directors is responsible for the preparation of the Restated Consolidated Financial Information for the purpose of inclusion in the offer document to be filed with Stock Exchange, Securities and Exchange Board of India, and Registrar of Companies, Mumbai in connection with the proposed SME IPO. The Restated Consolidated Financial Information have been prepared by the management of the Company as at and for the Financial Year ending March 31, 2023, March 31, 2022 and March 31, 2021 on the basis of preparation stated in "Note 2 A" of the Restated Consolidated Financial Information. The Board of Directors of the company's responsibility includes designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Consolidated Financial



G. P. KAPADIA & CO.

Information. The Board of Directors is also responsible for identifying and ensuring that the Company complies with the Act, ICDR Regulations and the Guidance Note.

3. We have examined such Restated Consolidated Financial Information taking into consideration:
 - a) The terms of reference and terms of our engagement agreed upon with you in accordance with our engagement in connection with the proposed SME IPO of equity shares of the Company;
 - b) The Guidance Note, requiring compliance with the ethical requirements of the Code of ethics, issued by the ICAI;
 - c) Concepts of test checks and materiality to obtain reasonable assurance based on verification of evidence supporting the Restated Consolidated Financial Information; and
 - d) The requirements of Section 26 of the Act and the ICDR Regulations. Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Act, the ICDR Regulations and the Guidance Note in connection with the IPO.
4. Restated Consolidated Financial Information have been prepared by the management from Audited Consolidated Financial Statements of the Group, its Joint Ventures and its associates as at and for the year ended at March 31, 2023, March 31, 2022 and March 31, 2021, in accordance with the Accounting Standards as prescribed under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014, as amended, and other accounting principles generally accepted in India, which have been approved by the Board of Directors at their meeting held on August 21 2023, November 15, 2022 and January 14, 2022 respectively.
5. For the purpose of our examination, we have relied on:
 - a) Auditors' reports issued by us dated August 21, 2023 on the Consolidated Financial Statement of the Group, its Joint Ventures and Associates as at and for the year ended March 31st 2023. These Consolidated Financial Statement were prepared by the management based on the Audited Financial Statements of the Company, its Subsidiaries and Joint Ventures audited by other auditors and unaudited and Management certified Financial Statement of its Associate, as at and for the year ended March 31, 2023. Unaudited and management certified financial statement of Associate, in our opinion and according to the information and explanation given by the management, are not material. Our opinion is not modified in respect of this matter.
 - b. Auditor' Report dated November 15, 2022 and January 14, 2022, issued by the previous Auditor- M/s Shani Shah & Associates, on the Audited consolidated financial statements of the Group, its Joint Ventures and its Associates as at and for the years ended March 31, 2022 and March 31, 2021 respectively and accordingly reliance had been placed on these Audited consolidated financial statement for the said years.

Above audited Consolidated Financial statements for the Financial Year ended March 31, 2021 were based on Management certified unaudited Financial Statements of Subsidiaries, Joint Ventures and Associates. Management had re-prepared Consolidated Financial statements for the Financial year ended March 31, 2021 considering audited financial statements of subsidiaries, Joint Ventures and



G. P. KAPADIA & CO.

Associate, audited by other Auditors, reviewed by us and included in the restated consolidated financial statements. Our opinion on the restated consolidated financial statements is not modified in respect of these matters.

- c. Reports of the audited financial statements of subsidiaries, Joint Ventures and Associate of the company, audited by other auditors, wherever applicable, have been furnished to us by the Management of the Company. Our opinion on the Restated Consolidated Financial Statements prepared by the Management as at and for the year March 31, 2023, March 31, 2022 and March 31, 2021, in so far as it relates to the amounts and disclosures included in respect of these Subsidiaries, Joint Ventures and Associate are based solely on the report(s) of such other auditors. Financial results of subsidiaries, joint ventures and Associate located outside India have been prepared and audited in accordance with IFRS for SME/IFRS/IAS/Companies Act in their respective countries. Our conclusion, in so far as it relates to the balances and affairs of such subsidiaries, joint venture and Associates located outside India, is based on the report of other auditors and the conversion adjustments prepared by the management of the Company and reviewed by us. Our opinion on the restated consolidated financial statements is not modified in respect of these matters.

The Company's management has converted the financial statements of such subsidiaries, Joint Ventures and Associate located outside India from IFRS for SME/IFRS/IAS/Companies Act applicable in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the management.

Reconciliation, on Profit and Networth of Audited Consolidated Financial Statement mentioned in Para 'b' above, is furnished in Note 29 of the Restated Consolidated Financial Information.

6. As indicated in our report above (Paragraph 5a and 5b), we did not audit the financial statements of the subsidiaries, Joint Ventures and Associate of the company, whose financial statements reflects total Assets, total Income and net cash inflow/(out flow) included in the restated Consolidated Financial Information as tabulated below:

Particulars	As at and for the year ended March 31, 2023 (Rs. In Lacs)	As at and for the year ended March 31, 2022 (Rs. In Lacs)	As at and for the year ended March 31, 2021 (Rs. In Lacs)
Total Asset	6,054.43	4,929.17	4,412.00
Total Revenue	4,342.47	3,626.52	2,797.96
Net Cash inflow/(out flow)	(31.95)	25.32	92.07
Profit/(Loss) of the Associates	0.24	(7.56)	(2.98)



G. P. KAPADIA & CO.

7. Based on our examination and according to the information and explanations given to us and also as per the reliance placed on the audit report submitted by the Auditors for the respective years, the Restated Consolidated Financial Information:
- a) have been prepared after incorporating adjustments for the changes in accounting policies, material errors and regrouping/reclassifications, in the financial period ended March 31, 2023, March 31, 2022 and March 31, 2021 to reflect the same accounting treatment as per the accounting policies and grouping/classifications followed as at and for the period ended March 31, 2023, if any.
 - b) do not contain qualification requiring adjustment for modification as there is no modification in the underlying audit reports for the Financial Statement of March 31, 2023, March 31, 2022 and March 31, 2021.
 - c) have been prepared after incorporating adjustments for prior period and other material amounts in the respective financial years to which they relate and there are no qualifications which require adjustments;
 - d) do not contain any Extra-ordinary items that needs to be disclosed separately in the accounts, wherever required;
 - e) have been prepared in accordance with the Act, the ICDR Regulations and the Guidance Note;
 - f) adequate disclosure has been made in the financial statements as required to be made by the issuer as per schedule III of the Companies Act, 2013 and;
8. Based on our examination and according to the information and explanations given to us, we report that:
- a) The "Restated Consolidated Statement of Assets and Liabilities" as set out in Annexure I to this report, of the Company as at year ended March 31, 2023, March 31, 2022 and March 31, 2021, is prepared by the Company and approved by the Board of Directors. These Restated Consolidated Statement of Assets and Liabilities, have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Restated Consolidated Financial Information as set out in Annexure IV to this Report
 - b) The "Restated Consolidated Statement of Profit and Loss" as set out in Annexure II to this report, of the Company for the year ended March 31, 2023, March 31, 2022 and March 31, 2021 are prepared by the Company and approved by the Board of Directors. These Restated Consolidated Statement of Profit and Loss have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Restated Consolidated Financial Information as set out in Annexure IV to this Report.



G. P. KAPADIA & CO.

- c) The “Restated Consolidated Cash Flow Statement” as set out in Annexure III to this report, of the Company for the year ended March 31, 2023, March 31, 2022 and March 31, 2021 are prepared by the Company and approved by the Board of Directors. Restated Consolidated Cash Flow Statement have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Restated Consolidated Financial Information as set out in Annexure IV to this Report.
9. We have also examined the following other financial information relating to the company prepared by the management and as approved by the Board of Directors of the company and annexed to this report relating to the company for the financial year ended March 31, 2023, March 31, 2022 and March 31, 2021 proposed to be included in the offer document.

Restated Consolidated Share Capital	Appearing in Note 3
Restated Consolidated Reserves and Surplus	Appearing in Note 4
Restated Consolidated Long Term Borrowings	Appearing in Note 5
Restated Consolidated Short Term Borrowings	Appearing in Note 6
Restated Consolidated Trade Payables	Appearing in Note 7
Restated Consolidated Other Current Liabilities	Appearing in Note 8
Restated Consolidated Short Term Provisions	Appearing in Note 9
Restated Consolidated Property, Plant & Equipment and Intangible Assets	Appearing in Note 10
Restated Consolidated Non-Current Investments	Appearing in Note 11
Restated Consolidated Long Term Loans and Advances	Appearing in Note 12
Restated Consolidated Other Non-Current Assets	Appearing in Note 13
Restated Consolidated Trade Receivables	Appearing in Note 14
Restated Consolidated Cash and Cash Equivalents	Appearing in Note 15
Restated Consolidated Short Term Loans and Advances	Appearing in Note 16
Restated Consolidated Other Current Assets	Appearing in Note 17
Restated Consolidated Revenue from Operations	Appearing in Note 18
Restated Consolidated Other Income	Appearing in Note 19
Restated Consolidated Employee Benefit Expenses	Appearing in Note 20
Restated Consolidated Finance Cost	Appearing in Note 21
Restated Consolidated Depreciation & Amortization	Appearing in Note 22
Restated Consolidated Other administrative Expenses	Appearing in Note 23
Restated Consolidated Related Party Transactions	Appearing in Note 24



G. P. KAPADIA & CO.

Restated Consolidated Accounting Ratios	Appearing in Note 25
Restated Contingent Liability and Commitments	Appearing in Note 26
Restated Statement of EPS	Appearing in Note 27
Restated Statement of Capitalisation	Appearing in Note 28
Restated Reconciliation of Profit and Net worth	Appearing in Note 29
Restated Segment Reporting	Appearing in Note 30
Material events occurring after the date of Restated Consolidated Statement of Assets and Liabilities	Appearing in Note 31
Material Adjustment to Restated Consolidated Financial Information {as per SEBI (ICDR) Regulations, 2018}	Appearing in Note 32
Additional Notes as per schedule III of Companies Act, 2013	Appearing in Note 33
Other Restated Financial Information	Appearing in Note 34

10. We, M/s G.P Kapadia & Co, Chartered Accountants have been subjected to the peer review process of the Institute of Chartered Accountants of India (“ICAI”) and hold a valid peer review certificate issued by the “Peer Review Board” of the ICAI.
11. The preparation and presentation of the Restated Consolidated Financial Information referred above are based on the Consolidated Audited financial statements of the Company and are in accordance with the provisions of the Act and ICDR Regulations. The Restated Consolidated Financial Information and information referred to above is the responsibility of the management of the Company.
12. The report should not in any way be construed as a re-issuance or re-dating of any of the previous audit reports issued by any other Firm of Chartered Accountants nor should this report be construed as a new opinion on any of the financial statements referred to therein.
13. We have no responsibility to update our report for events and circumstances occurring after the date of the report.
14. In our opinion, the above Restated Consolidated Financial Information contained in Annexure – I to IV to this report read along with the Significant Accounting Policies and Notes to Accounts to restated Consolidated Financial Information as set out in Annexure IV are prepared after making adjustments and regrouping as considered appropriate and have been prepared in accordance with the Companies Act, SEBI (ICDR) Regulations, our engagement with you and Guidance Note published by ICAI with this regard.



G. P. KAPADIA & CO.

15. Our report is intended solely for use of the management and for inclusion in the Offer Document in connection with the SME IPO for Proposed Issue of Equity Shares of the Company and our report should not be used, referred to or distributed for any other purpose without our prior consent in writing.

For G.P. Kapadia & Co.
Chartered Accountants
ICAI Firm Registration No. 104768W

Atul Desai



Atul Desai
Partner
Membership No. 030850
Place-Mumbai
Date- 21st August 2023
UDIN- 23030850BGRKGE3431

Annexure I
UNIHEALTH CONSULTANCY LIMITED
(Formerly known as Unihealth Consultancy Private Limited)
Restated Consolidated Statement of Assets and Liabilities
CIN: U85100MH2010PLC200491

(₹ In Lakhs)

Particulars	Note No.	As at 31 March, 2023	As at 31 March, 2022	As at 31 March, 2021
A EQUITY AND LIABILITIES				
1 Shareholders' Funds				
(a) Share capital	3	138.95	134.19	134.19
(b) Reserves and surplus	4	2,612.83	1,344.98	936.17
		2,751.78	1,479.17	1,070.36
(c) Minority Interest		(24.28)	(22.19)	(11.86)
3 Non-current Liabilities				
(a) Long-term borrowings	5	3,569.54	3,593.47	3,691.97
(b) Deferred Tax Liability (Net)		87.54	122.63	52.38
(c) Other long-term liabilities		-	-	-
(d) Long-term provisions		-	-	-
		3,657.08	3,716.10	3,744.35
4 Current Liabilities				
(a) Short-term borrowings	6	357.13	207.83	179.07
(b) Trade payables				
(i) Total outstanding dues of micro enterprises and small enterprises	7	13.36	0.55	-
(ii) Total outstanding dues to creditors other than micro enterprises and small enterprises	7	282.63	180.77	155.09
(c) Other current liabilities	8	555.37	844.87	689.45
(d) Short-term provisions	9	240.25	71.55	12.41
		1,448.74	1,305.57	1,036.02
TOTAL		7,833.32	6,478.65	5,838.87
B ASSETS				
1 Non-current Assets				
(a) Property, plant and equipments and Intangible Asset				
- Property, Plant and Equipment		2,945.66	2,829.59	2,762.21
- Intangible assets	10	10.82	11.96	13.53
- Goodwill on consolidation		751.46	742.92	742.92
- Capital Work in Progress		-	48.75	45.72
- Intangible Assets under development		-	-	-
(b) Non-current investments	11	28.71	28.47	36.03
(c) Deferred tax assets (net)		-	-	-
(d) Long-term loans and advances	12	677.40	335.28	265.12
(e) Other non-current assets	13	94.99	64.86	58.06
		4,509.04	4,061.83	3,923.59
2 Current Assets				
(a) Current investments		-	-	-
(b) Inventories		211.24	179.73	146.12
(c) Trade receivables	14	2,739.36	1,819.26	1,418.62
(d) Cash and cash equivalents	15	195.38	234.97	205.03
(e) Short-term loans and advances	16	178.30	176.53	144.11
(f) Other current assets	17	-	6.33	1.40
		3,324.28	2,416.82	1,915.28
TOTAL		7,833.32	6,478.65	5,838.87

Significant Accounting policies and Notes to the Restated Consolidated financial statements (Note 1-35)

As per our report of even date attached.

G P Kapadia & Co,
Chartered Accountants
Firm registration No: 104768W


Atul B Desai
Partner
Membership No. 030850
Mumbai
Date- 21st August 2023




For and on behalf of the Board of Directors
Unihealth Consultancy Limited


Akshay M Parmar
Managing Director
DIN:01533004


Prajakta Suresh Bhor
Company Secretary
Membership No.:A55171


Anurag Shah
Director
DIN:02544806


Parag Shah
Whole Time Director
& Chief Financial Officer
DIN: 07773426



Annexure II
UNIHEALTH CONSULTANCY LIMITED
(Formerly known as Unihealth Consultancy Private Limited)
Restated Consolidated Statement of Profit and Loss
CIN: U85100MH2010PLC200491

(₹ in Lakhs)

	Particulars	Note No.	For the year ended 31 March, 2023	For the year ended 31 March, 2022	For the year ended 31 March, 2021
I	Revenue from operations (Net)	18	4,393.86	3,683.21	2,620.78
II	Other income	19	209.15	109.48	242.73
III	Total Income (I+II)		4,603.01	3,792.69	2,863.51
IV	Expenses				
	Purchase of Stock in Trade		700.41	871.60	693.35
	Change in Inventories		27.82	(33.26)	(71.61)
	Employee benefits expense	20	647.73	585.98	460.26
	Finance costs	21	412.13	518.51	128.85
	Depreciation and amortisation expense	22	251.62	221.23	218.37
	Other expenses	23	1,635.52	1,108.28	886.88
	Total Expenses		3,675.23	3,272.34	2,316.10
V	Profit before Exceptional ,Extraordinary items and Tax		927.78	520.35	547.41
VI	Exceptional items		-	-	-
VII	Profit before Extraordinary items and Tax		927.78	520.35	547.41
VIII	Extraordinary Items		-	-	-
IX	Profit before Tax		927.78	520.35	547.41
X	Tax expense:				
	(a) Current tax		206.70	77.39	-
	(b) Deferred tax		(44.59)	63.71	52.38
	Total Tax Expense		162.11	141.10	52.38
XI	Profit / (Loss) for the period from continuing operations, before minority interest (IX-X)		765.67	379.25	495.03
XII	Profit / (Loss) for the period from discontinuin operations		-	-	-
XIII	Less: Minority Interest - Share of Profit/(Loss) .		(2.09)	(10.33)	(8.84)
XIV	Add: Share of Profit or loss from Assoiate co (After Tax)		0.24	(7.56)	(2.98)
XV	Profit/(loss) for the Year		768.00	382.02	500.89
XVI	Earnings per share (of Rs 10/- each):				
	Basic (Rs)*		6.94	3.45	4.53
	Diluted (Rs)*		6.94	3.45	4.53

*a) 97,26,458 no. of Bonus Shares in the ratio of 7:1, based on the shareholding as on 31/03/2023, issued by the company post restated consolidated financial information period but before filing of RHP, is considered for the computation of Basic & Diluted EPS and in line of AS - 20. For the purpose of rational comparision, the Basic & Diluted EPS is computed, as if, the bonus shares are issued as on the 01st April of first year of restated Consolidated financial Information.

Significant Accounting policies and Notes to the Restated Consolidated financial statements (Note 1-35)
As per our report of even date attached

G P Kapadia & Co,
Chartered Accountants
Firm registration No: 104768W

Atul B Desai
Atul B Desai
Partner
Membership No. 030850
Mumbai
Date- 21st August, 2023



For and on behalf of the Board of Directors
Unihealth Consultancy Limited

Akshay M Parmar
Akshay M Parmar
Managing Director
DIN:01533004

Prajakta Suresh Bhor
Company Secretary
Membership No.: A55171

Anurag Shah
Anurag Shah
Director
DIN:02544806

Parag Shah
Parag Shah
Whole Time Director
& Chief Financial Officer
DIN: 07773426



Annexure III
UNIHEALTH CONSULTANCY LIMITED
(Formerly known as Unihealth Consultancy Private Limited)
Restated Consolidated Cash Flow Statement
CIN: U85100MH2010PLC200491

(₹ in Lakhs)

Particulars	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
A Cash flow from operating activities			
Net profit before tax	927.78	520.35	547.41
Adjustments for:			
Depreciation/amortization	251.62	221.23	218.37
Loss/(Profit) on sale of Fixed Asset	(2.37)	-	-
Balances Written (Back)/Off	(8.27)	-	(104.01)
Finance Cost	412.13	518.51	128.85
Rent Receipts	(1.76)	-	-
Int on Income tax refund	(0.03)	-	-
Foreign Exchange (Gain)/Loss	(121.28)	(53.30)	(82.40)
Insurance Claim Received	(17.88)	-	-
Interest on FD & Loan given	(56.31)	(35.23)	(0.54)
Operating profit before working capital changes	1,383.63	1,171.56	707.68
Changes in assets and liabilities:			
(Increase) / decrease in Inventories	(31.51)	(33.61)	(71.54)
(Increase) / decrease in Trade Receivables	(920.10)	(400.64)	(163.42)
(Increase) / decrease in Short Term Loans and Advances	(1.77)	(32.42)	122.02
(Increase) / decrease in Current and Non Current Assets	(23.77)	(11.74)	(1.48)
Increase / (decrease) in Current and Non Current Liabilities	(254.43)	225.69	127.52
Increase / (decrease) in Long term and Short term Provisions	20.12	(0.64)	(5.20)
Increase / (decrease) in Trade Payables	122.94	26.23	(310.04)
Cash (used in)/ generated from operating activities	295.11	944.43	405.54
Income tax paid	(162.11)	(17.61)	-
Net cash from/ (used in) from operating activities (A)	133.00	926.82	405.54
B Cash flow from Investing activities			
(Increase) / decrease in long term loans & advances	(342.12)	(70.17)	-
Interest on FD & Loan given	56.31	35.23	0.54
Sale of Fixed Asset	22.07	-	-
Rent Receipts	1.76	-	-
Loss/(Profit) on sale of assets	2.37	-	-
Purchase of fixed assets	(231.97)	(130.00)	(35.81)
Net cash from/ (used in) from investing activities (B)	(491.58)	(164.94)	(35.27)
C Cash flow from Financing activities			
Proceeds/(Repayment) of Borrowings (Note 4)	625.37	(69.76)	(196.49)
Foreign Exchange Gain/(Loss)	121.28	53.30	-
Issue of Shares	-	-	-
Finance cost	(412.13)	(518.51)	(128.85)
Net cash from / (used in) from financing activities (C)	334.52	(534.97)	(325.34)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	(24.06)	226.91	44.93
Cash and cash equivalents at the beginning of the year	234.97	205.03	119.99
Effect of Foreign Exchange Gain or Loss	(15.53)	(196.97)	40.11
Cash and cash equivalents at the end of the year	195.38	234.97	205.03

- Notes:**
- The cash flow statement has been prepared in accordance with the requirements of Accounting standard - 3 - Cash flow Statement issued in terms of section 133 of the Companies Act, 2013.
 - The figures in brackets indicate outflows of cash and cash equivalents.
 - Previous year's figures have been regrouped, rearranged wherever necessary.
 - Pursuant to a resolution passed by Board of Directors of the company, at their meeting held on March 30, 2023, Conversion of Loan of Rs.500 Lacs into 47,619 no. of Equity shares of the company issued at a price of Rs. 1050 (including premium of Rs. 1040) in case of shareholder Mr. Shantilal Kataria was approved.

As per our report of even date attached

G P Kapadia & Co,
Chartered Accountants
Firm registration No: 104768W

Anil B Desai
Anil B Desai
Partner
Membership No. 30850
Mumbai
Date- 21st August 2023



For and on behalf of the Board of Directors
Unihealth Consultancy Limited

Anam
Akshay M Parmar
Managing Director
DIN:01533004

Prajakta
Prajakta Suresh Bhor
Company Secretary
Membership No.: A55171

Aslak
Anurag Shah
Director
DIN:02544806

P. Shah
Parag Shah
Whole Time Director
& Chief Financial Officer
DIN: 07773426



Annexure IV
UNIHEALTH CONSULTANCY LIMITED
(Formerly known as Unihealth Consultancy Private Limited)
Significant Accounting policies and Notes to the Restated Consolidated Financial Information

Note	Particulars
------	-------------

1 Corporate information

Unihealth Consultancy Private Limited ("Company" "Holding Company") was incorporated on 26/02/2010 having CIN U85100MH2010PLC200491. The Company is engaged in Medical Tourism. Company provides complete healthcare solutions with presence in segments ranging from Consultancy Services and Hospital Management to Pharmaceuticals and Equipment supplies. Name of the Company was changed from Unihealth Consultancy Private Limited (CIN U85100MH2010PTC200491) to Unihealth Consultancy Limited (CIN U85100MH2010PLC200491) w.e.f. 26th April, 2023 vide Certificate of Incorporation Consequent upon conversion to public company issued by ROC Mumbai. Hence, in connection with proposed SME Initial Public Offer of Equity Shares (SME IPO), Restated Consolidated Financial information comprising of Restated Consolidated Statement of Assets and Liabilities as at March 31, 2023, March 31, 2022 and March 31, 2021, the Restated Consolidated Statement of Profit and Loss, the Restated Consolidated Cash Flow Statement for the Period ended on March 31, 2023, March 31, 2022 and March 31, 2021 (Annexure I -IV) for its inclusion in RHP/ Offer Document, is prepared in the name of the Unihealth Consultancy Limited (CIN U85100MH2010PLC200491).

The Holding Company has Four subsidiaries, Two Joint Venture concerns and an Associate viz. (a) Aryavarta FZE (United Arab Emirates) (b) Bio Health Limited (United Republic of Tanzania) (c) Unihealth (T) Limited (United Republic of Tanzania) (d)Unhealth Pharmaceuticals Private Limited (e) UMC Global Health Limited (Federal Republic of Nigeria) (f)Victoria Hospitals Limited (Joint Venture) (Republic of Uganda) (g) Unihealth Uganda Limited (Republic of Uganda) .

1.1 Proportion of ownership interest in Subsidiaries and Associate Company included in consolidation:

Name of the Company	Nature of Interest	Date of Investment	Proportion of Ownership Interest		
			As at 31-03-2023	As at 31-03-2022	As at 31-03-2021
Aryavarta FZE	Subsidiary	15.07.2014	100%	100%	100%
Biohealth Limited	Subsidiary	01.01.2016	99.01%	99.01%	99.01%
Unihealth (T) Limited	Subsidiary	31.03.2017	80%	80%	80%
Unihealth Pharmaceuticals Private Limited	Subsidiary	15.03.2023	100%	-	-
Unihealth Uganda Limited	Associate	18.07.2016	45%	45%	45%
UMC Global Health Limited	Joint Venture	31.03.2017	50%	50%	50%
Victoria Hospitals Limited	Joint Venture	10.10.2016	50%	50%	50%




UNIHEALTH CONSULTANCY LIMITED
(Formerly known as Unihealth Consultancy Private Limited)
Significant Accounting policies and Notes to the Restated Consolidated financial Information

Note	Particulars
2	<p>Significant accounting policies</p> <p>A Basis of accounting and preparation of Financial Statements</p> <p>The restated consolidated statement of assets and liabilities of the Company as at March 31, 2023, 2022, and 2021 and the related restated consolidated statement of Profit and Loss and restated consolidated cash flow statement for the period/year ended March 31, 2023, 2022 and 2021 (herein after collectively referred to as ("Restated Consolidated Financial Information") have been compiled by the management from the audited Consolidated Financial Statements for the period/year ended on March 31, 2023, 2022 and 2021. Restated Consolidated Financial Informations have been prepared to comply in all material respects with the provisions of Part I of Chapter III of the Companies Act, 2013 (the "Act") read with Companies (Prospectus and Allotment of Securities) Rules, 2014, Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations") issued by SEBI and Guidance note on Reports in Companies Prospectuses (Revised 2019) ("Guidance Note"). Restated Consolidated Financial Information have been prepared specifically for inclusion in the offer document to be filed by the Company with the SME platform of NSE in connection with its proposed IPO. The Company's management has recasted the Consolidated Financial Statements in the form required by Schedule III of the Companies Act, 2013 for the purpose of restated Consolidated Financial Information.</p> <p>The financial statements of the Group are prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the accounting standards as prescribed under Section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Companies Act, 2013 (to the extent notified). The financial statements are prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.</p> <p>B Principle of Consolidation</p> <p>The accompanying consolidated financial statements have been prepared in accordance with Accounting Standard 21 'Consolidated Financial Statements'. The Standalone financial statements of Unihealth Pharmaceuticals Private Limited Aryavarta FZE, Unihealth Tanzania Ltd, Bio Health Limited, Victoria Hospitals Limited and UMC Global Health Limited have been prepared under the historical cost convention and in accordance with International Financial Reporting Standards (IFRS), IFRS for SME and International Accounting Standards. Financials of all the subsidiary and Joint ventures and Associates companies which are considered for preparation of consolidated accounts are audited and prepared as per prevailing law in that countries.</p> <p>The financial statement of the Holding company and its subsidiaries and Joint venture have been combined on line-by-line basis by adding together book value of items of assets, liabilities, income and expenses after eliminating intra-group balances and transactions and resulting unrealized gain/loss. Goodwill / Capital Reserve has been recorded to the extent of difference between cost of acquisition and fair value of the net assets in the acquired company at the date of acquisition. Exchange differences resulting from difference due to transactions of foreign currency assets and liabilities in foreign subsidiaries is disclosed as 'Foreign Currency Translation Reserve'. The foreign operations of subsidiaries and Joint venture, have been accounted for as per Accounting Standard-11 taking the same as Non-Integral Foreign Operation. The consolidated financial statements are prepared applying uniform accounting policies in use at Holding company and its subsidiaries and Joint venture. Wherever, there is difference in accounting policy followed, the same has been appropriately disclosed.</p>



2.1	Use of estimates The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known or materialise.																												
2.2	Property, Plant and Equipments PPE is stated at acquisition cost, net of accumulated depreciation and accumulated impairment losses, if any. Cost of acquisition of property, plant and equipment is inclusive of freight, import duties, non- refundable taxes and other directly attributable expenses incurred to bring the assets to their working condition for intended use. Subsequent costs related to an item of PPE are recognised in the carrying amount of the item if the recognition criteria are met.																												
2.3	Intangible assets Intangible assets are recorded at the consideration paid for acquisition of such assets and are carried at cost less accumulated amortization and impairment.																												
2.4	Capital Work in progress Expenditure/Income during construction period (including Finance cost related to borrowed funds for construction or acquisition of qualifying PPE) is included under capital work in progress, and the same is allocated to the respective PPE on the completion of their PPE.																												
2.5	Depreciation and amortisation In case of Indian companies, Depreciation is provided on Written Down Value Method based on the useful lives of the assets as estimated by the management and is charged to the Statement of Profit and Loss as per the requirement of Schedule II of the Companies Act, 2013. Intangible Assets are to be amortized on a Straight Line basis over the estimated useful economic life. In case of Bio health Limited , Depreciation is calculated on the written down value (WDV) method to write off the cost of each asset to its residual values over its estimated useful life by charging following annual rates for depreciation. Intangible Assets are to be amortised on a straight line basis at the rate of 10% over the estimated useful economic life of the assets. <table border="0" style="width: 100%;"> <tr> <td style="width: 80%;">Furniture-Fixtures & Medical Equipments</td> <td style="text-align: right;">12.50%</td> </tr> <tr> <td>Motor Vehicles & Compute-accessories</td> <td style="text-align: right;">37.50%</td> </tr> </table> In case of Unihealth Tanzania Limited , Depreciation is calculated on the written down value (WDV) method to write off the cost of each asset to its residual values over its estimated useful life by charging following annual rates for depreciation. Intangible Assets are to be amortised on a straight line basis at the rate of 10% over the estimated useful economic life of the assets. <table border="0" style="width: 100%;"> <tr> <td style="width: 80%;">Furniture-Fixtures & Medical Equipments</td> <td style="text-align: right;">12.50%</td> </tr> <tr> <td>Compute-accessories</td> <td style="text-align: right;">37.50%</td> </tr> <tr> <td>Motor vehicles</td> <td style="text-align: right;">25%</td> </tr> </table> In case of Victoria Hospital Limited, Depreciation is calculated on the written down value (WDV) method to write off the cost of each asset to its residual values over its estimated useful life by charging following annual rates for depreciation. <table border="0" style="width: 100%;"> <tr> <td style="width: 80%;">Furniture-Fixtures & Lease Hold Improvements</td> <td style="text-align: right;">20%</td> </tr> <tr> <td>Medical & other Equipments</td> <td style="text-align: right;">12.50%</td> </tr> <tr> <td>Computer Equipments</td> <td style="text-align: right;">40%</td> </tr> <tr> <td>Motor Vehicle</td> <td style="text-align: right;">15%</td> </tr> </table> In case of UMC Global health limited, Depreciation is calculated on the written down value (WDV) method to write off the cost of each asset to its residual values over its estimated useful life by charging following annual rates for depreciation. Further in the said company assets bifurcation is as per the law prevailing in the country in which it operate i.e. car medical , Medical equipments, Air conditioned, Tele vision etc are covered under plant and machinery. <table border="0" style="width: 100%;"> <tr> <td style="width: 80%;">Furniture-Fixtures</td> <td style="text-align: right;">15%</td> </tr> <tr> <td>Vehicles, Medical Equipments and computers</td> <td style="text-align: right;">25%</td> </tr> </table> In case of Unihealth Uganda Limited, Depreciation is calculated on the written down value (WDV) method to write off the cost of each asset to its residual values over its estimated useful life by charging following annual rates for depreciation. Further in the said company assets bifurcation is as per the law prevailing in the country in which it operate i.e. car medical , Medical equipments, Air conditioned, Tele vision etc are covered under plant and machinery. <table border="0" style="width: 100%;"> <tr> <td style="width: 80%;">Motor Vehicles</td> <td style="text-align: right;">20%</td> </tr> <tr> <td>Furniture and Fixtures</td> <td style="text-align: right;">10%</td> </tr> <tr> <td>Office Equipments</td> <td style="text-align: right;">10%</td> </tr> </table>	Furniture-Fixtures & Medical Equipments	12.50%	Motor Vehicles & Compute-accessories	37.50%	Furniture-Fixtures & Medical Equipments	12.50%	Compute-accessories	37.50%	Motor vehicles	25%	Furniture-Fixtures & Lease Hold Improvements	20%	Medical & other Equipments	12.50%	Computer Equipments	40%	Motor Vehicle	15%	Furniture-Fixtures	15%	Vehicles, Medical Equipments and computers	25%	Motor Vehicles	20%	Furniture and Fixtures	10%	Office Equipments	10%
Furniture-Fixtures & Medical Equipments	12.50%																												
Motor Vehicles & Compute-accessories	37.50%																												
Furniture-Fixtures & Medical Equipments	12.50%																												
Compute-accessories	37.50%																												
Motor vehicles	25%																												
Furniture-Fixtures & Lease Hold Improvements	20%																												
Medical & other Equipments	12.50%																												
Computer Equipments	40%																												
Motor Vehicle	15%																												
Furniture-Fixtures	15%																												
Vehicles, Medical Equipments and computers	25%																												
Motor Vehicles	20%																												
Furniture and Fixtures	10%																												
Office Equipments	10%																												



2.6	<p>Revenue recognition</p> <p>Income from services Revenue is recognised to the extent it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.</p> <p>Revenue from rendering of services are recognised as the Service is performed, either by the proportionate completion method or by the completed service contract method.</p> <p>Other income Interest income is accounted on accrual basis. Dividend income is accounted, when the right to receive the dividend is established.</p> <p>Sale of Goods -In case of Biohealth Limited and Unihealth Tanzania Limited Sale of goods are recognised when entity has delivered the products to the customer, the customer has accepted the products and collectability of the related receivables is reasonably used.</p> <p>-In case of UMC Global Health Limited and Unihealth Pharmaceuticals Private Limited Revenue from sale of goods is recognized when significant risk and rewards of ownership of goods have been passed to the buyer.</p> <p>-In case of Unihealth Uganda limited Sale are recognised on delivery of goods, raising of invoices or cash sales.</p> <p>-In case of Victoria Hospitals Limited Sale of goods are recognised upon delivery of products and customer acceptance.</p>
2.7	<p>Foreign currency transactions and translations</p> <p>Initial recognition Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.</p> <p>Measurement of foreign currency monetary items at the Balance Sheet date Foreign currency monetary items (other than derivative contracts) of the Company and outstanding at the Balance Sheet date are restated at the year-end rates.</p> <p>Assets and liabilities are translated at the exchange rate prevailing on the Balance Sheet date. Exchange differences arising out of these translations are charged to the Foreign currency translation reserve and disclosed in note for Reserves and Surplus.</p>
2.8	<p>Investments</p> <p>Long-term investments are valued at cost. Provision for diminution, if any, in the value of investment is to be made to recognise a decline, other than temporary, in the opinion of the Management.</p> <p>Current Investment are to be carried at the lower of cost and fair value, determined on a category-wise basis.</p>
2.9	<p>Provisions and Contingencies</p> <p>A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. These are determined based on the best estimate required to settle the obligation at the Balance Sheet date.</p> <p>A Present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount can not be made is disclosed as a contingent Liability. Contingent Liability are also disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not within the control of the company.</p>
2.10	<p>Earnings per share</p> <p>Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares.</p>



2.11	<p>Taxes on income Current Tax is measured on the basis of estimated taxable income for the current accounting period in accordance with the applicable tax rates and the provisions of the Income tax Act, 1961 and other applicable Tax laws.</p> <p>Income tax comprises the net changes in the deferred tax assets or liabilities in the year. Deferred tax liabilities are recognized for the future tax consequences of temporary differences between the carrying values of assets and liabilities and their respective bases.</p>
2.12	<p>Cash and cash equivalents Cash and Cash equivalents comprises cash at Bank and in hand and short term deposits that are readily convertible in to cash which are subject to insignificant risk of changes in value and held for the purpose of meeting short term cash commitments.</p>
2.13	<p>Current & Non Current Classification All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set-out in the Act. Deferred tax assets and liabilities are classified as non-current assets and non-current liabilities, as the case may be.</p>
2.14	<p>Segment Reporting Segments are identified as Business and Geographic Segments in line with the guiding principles given in Accounting Standard 17.</p>
2.15	<p>Borrowing cost As per AS 16, borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.</p>
2.16	<p>Inventories Inventories are stated at the lower of cost or net realisable value. Cost is determined using the weighted average or first in, first out (FIFO) method. The cost of finished goods and work in progress comprises raw material, direct labor, other direct cost and other related production overheads (based on normal operating capacity) but excludes borrowing cost.</p>
2.17	<p>Employees benefits expenses In case of Indian company, employee benefits like salary, wages, bonus are recognised as an expense in the period in which the employees renders the related service. The Company contribute to provident fund under the Provident Fund Act. For defined benefit plans in the form of gratuity, the cost of providing benefits is determined with actuarial valuations being carried out at Balance Sheet date.</p> <p>In case of Biohealth Limited and Unihealth tanzania Limited Termination benefits are recognised as an expense when the entity is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefit as a result of an offer made to encourage voluntary redundancy. Short term employees benefits are measured on undiscounted basis and are expensed as and when related services are provided.</p> <p>In case of victoria Hospital Limited and Unihealth Uganda Limited, The company and its employees contribute to the National Social Security Fund (NSSF), a statutory defined contribution scheme registered under NSSF Act. The company contribution to the defined contribution schemes are charged to profit and loss in the period in which they relate.</p> <p>In case of UMC Global, The company contribute in the applicable funds for the benefit of the employee.</p>



Notes forming part of the Restated Consolidated financial information

Note 3: Restated Consolidated Share Capital

(₹ in Lakhs)

Particulars	As at 31 March, 2023		As at 31st March, 2022		As at 31st March, 2021	
	Number of shares	Amount	Number of shares	Amount	Number of shares	Amount
(a) Authorised						
Equity share of Rs. 10 each	1,70,00,000	1,700.00	15,00,000	150.00	15,00,000	150.00
Preference Shares of Rs. 100 each	-	-	2,50,000	250.00	2,50,000	250.00
	1,70,00,000	1,700.00	17,50,000	400.00	17,50,000	400.00
(b) Issued, subscribed and fully paid-up						
equity shares of Rs 10 each fully paid up	13,89,494	138.95	13,41,875	134.19	13,41,875	134.19
Preference shares of Rs.100 each	-	-	-	-	-	-
Total	13,89,494	138.95	13,41,875	134.19	13,41,875	134.19

Notes:

(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:

Particulars	As at 31 March, 2023		As at 31st March, 2022		As at 31st March, 2021	
	Number of shares	Amount	Number of shares	Amount	Number of shares	Amount
At the Beginning of the Year	13,41,875	134.19	13,41,875	134.19	13,41,875	134.19
Add: Issued during the year*	47,619	4.76	-	-	-	-
Less: Bought back during the year	-	-	-	-	-	-
Closing balance at the end of the year	13,89,494	138.95	13,41,875	134.19	13,41,875	134.19

*Pursuant to a resolution passed by Board of Directors of the company, at their meeting held on March 30, 2023, Conversion of Loan of Rs. 500 Lacs into 47,619 no. of Equity shares of the company issued at a price of Rs. 1050 (including premium of Rs. 1040) in case of shareholder Mr. Shantilal Kataria was approved.

(ii) During the year, the authorised share capital of the Company Rs.400 Lakhs consisting of 15,00,000 Equity Shares of Rs.10 each and 2,50,000 9% Cumulative Redeemable Preference Shares of Rs.100 each are reclassified to Rs.400 Lakhs divided into 40,00,000 Equity Share of Rs.10 each. Further, the Company has increased the authorized share capital of the Company from Rs. 4,00,00,000 consisting of 40,00,000 Equity Shares of Rs. 10 each to Rs. 17,00,00,000 consisting of 1,70,00,000 Equity Shares of Rs. 10 each.

(iii) The holding company has following classes of share capital as under:

EQUITY SHARES (Face Value Rs. 10/- Per Share)

(a) Each Shareholder is eligible for one vote per share.

(b) The dividend proposed by Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend.

(c) In the event of liquidation, the shareholders of equity shares are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholdings.

(d) Details of shares held by the holding company, the ultimate holding company, their subsidiaries and associates: NIL

(e) Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March, 2023		As at 31st March, 2022		As at 31st March, 2021	
	Number of shares held	% holding	Number of shares held	% holding	Number of shares held	% holding
Equity shares with voting rights:						
Mr. Anurag Shah	6,25,000	44.98%	6,25,000	46.58%	6,25,000	46.58%
Mr. Akshay Parmar	5,22,500	37.60%	3,12,500	23.29%	3,12,500	23.29%
Mr. Prafulla Parmar	1,02,495	7.38%	3,12,495	23.29%	3,12,495	23.29%
Total	12,49,995	89.96%	12,49,995	93.15%	12,49,995	93.15%



@maumai

Note 3.1: Details of shares held by the Promoters

Sr. No	Name of the Promoter	March 31, 2023			March 31, 2022			March 31, 2021		
		No of Shares	% of Total Shares	% change during the year	No of Shares	% of Total Shares	% change during the year	No of Shares	% of Total Shares	% change during the year
1	Anurag Ratankumar Shah	6,25,000	44.98%	-1.60%	6,25,000	46.58%	0.00	6,25,000	46.58%	0.00
2	Akshay Mahendra Parmar	5,22,500	37.60%	14.32%	3,12,500	23.29%	0.00	3,12,500	23.29%	0.00

Note 3.2: Details of shares held by the Shareholders

1	Anurag Ratankumar Shah	6,25,000	0.45	-1.60%	6,25,000	46.58%	0.00	6,25,000	46.58%	0.00
2	Akshay Mahendra Parmar	5,22,500	0.38	14.32%	3,12,500	23.29%	0.00	3,12,500	23.29%	0.00
3	Prafulla Mahendra Parmar	1,02,495	0.07	-15.91%	3,12,495	23.29%	0.00	3,12,495	23.29%	0.00
4	Manthan Chinubhai Shah	6,500	0.00	-0.02%	6,500	0.48%	0.00	6,500	0.48%	0.00
5	Mayuri Akshay Parmar	9,600	0.01	-0.03%	9,625	0.72%	0.00	9,625	0.72%	0.00
6	Naitk Chinubhai Shah	12,500	0.01	-0.03%	12,500	0.93%	0.00	12,500	0.93%	0.00
7	Nikita D Punamiya	6,250	0.00	-0.02%	6,250	0.47%	0.00	6,250	0.47%	0.00
8	Rahul Vimalchand Gandhi	6,875	0.00	-0.02%	6,875	0.51%	0.00	6,875	0.51%	0.00
9	Rajendra Khapchand Kothari	6,250	0.00	-0.02%	6,250	0.47%	0.00	6,250	0.47%	0.00
10	Sangeeta R Shah	17,250	0.01	-0.04%	17,250	1.29%	0.00	17,250	1.29%	0.00
11	Santosh V Mehta	12,500	0.01	-0.03%	12,500	0.93%	0.00	12,500	0.93%	0.00
12	Shantilal B Kataria	47,644	0.03	3.43%	-	0.00%	0.00	-	0.00%	0.00
13	Swati R Gandhi	1,250	0.00	0.00%	1,250	0.09%	0.00	1,250	0.09%	0.00
14	Taraben C Shah	8,500	0.01	-0.02%	8,500	0.63%	0.00	8,500	0.63%	0.00
15	Uttamchand Ranawat	5	0.00	0.00%	5	0.00%	0.00	5	0.00%	0.00
16	Vasanti Gandhi	3,750	0.00	-0.01%	3,750	0.28%	0.00	3,750	0.28%	0.00
17	Vumalchand C Gandhi	625	0.00	0.00%	625	0.05%	0.00	625	0.05%	0.00
Total		13,89,494	100%	0.00	13,41,875	100%	0.00	13,41,875	100%	0.00



Amama

Notes forming part of the Restated Consolidated financial information

Note 4 : Restated Consolidated Reserves and Surplus

(₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
a	Capital Reserve (AS-21)			
	Opening balance	-	-	-
	Add/Less: Changes during the year	-	-	-
	Closing balance	-	-	-
b	Securities Premium Reserve			
	Opening balance	840.81	840.81	840.81
	Add/Less: Changes during the year	495.24		
	Closing balance	1,336.05	840.81	840.81
c	Consolidate Profit & Loss			
	Opening balance as per last Balance Sheet	943.81	609.57	(6.85)
	Add/less: Profit for the year	634.29	334.24	616.42
	Closing balance	1,578.10	943.81	609.57
d	Foreign Currency Translation Reserve			
	Opening Balance	13.91	(12.80)	(13.93)
	Add/Less: Changes during the year	22.76	26.71	1.13
	Closing balance	36.67	13.91	(12.80)
e	Surplus in Statement of Profit and Loss			
	Balance as per Balance Sheet	(453.55)	(501.41)	(386.01)
	Add: Profit/(Loss) for the year	133.71	47.78	(115.53)
	Less : Adjustment relating to Proposed Dividend and others	-	-	-
	Add : Adjustment relating to provision for tax for earlier year	-	-	-
	Less : Other Adjustment	(18.15)	0.08	0.13
	Closing balance	(337.99)	(453.55)	(501.41)
	Total	2,612.83	1,344.98	936.17

Note 5 : Restated Consolidated Long Term Borrowings

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
1	Secured			
a	Term loans			
-	From Bank			
	SIDBI Loan in Foreign Currency	-	11.00	26.71
	SIDBI Loan in Indian Rupees	4.77	11.91	21.43
	Bank of Baroda	1,353.44	1,658.17	1,869.74
	HDFC Bank	5.71	-	-
2	Unsecured			
a	Loan from Directors, Related Parties and shareholders	2,205.62	1,912.39	1,774.09
	Total	3,569.54	3,593.47	3,691.97

Refer note 5.1 for Terms, Conditions and Other Material Information in respect of Term Loans



Omama

Note 5.1 : Terms, Conditions and Other Material Information in respect of Term Loans						(₹ in Lakhs)
31-03-2023						
Sr. No	Particulars	Unihhealth Consultancy Limited		Unihhealth Pharmaceutical Pvt Ltd		
		SIDBI LOAN IN FOREIGN CURRENCY	SIDBI LOAN IN INDIAN CURRENCY	Bank of Baroda	HDFC Bank Ltd	
1	Nature of Loan	Foreign Currency Term Loan	Mortgage	CGTMSE	Business Loan	
2	Date of Disbursal	27.07.2018- 1st Tranche amounting to Rs. 30,00,000; 30.08.2018- 2nd and balance tranche amounting to Rs. 30,00,000	10-12-2020	04.12.2021	30-09-2021	
3	Loan Amount	INR 6000000 (USD ₹72.73)	21,43,000	32,50,000	24,99,999	
4	Repayment Mode	EMI	EMI	EMI	EMI	
5	Amount of each Instalment	US \$1819 for 47 months & 1 installment for US \$ 1780 in the last month	Principal payment of Rs.59,530/- for first 35 months & Rs.59,450/- for last month.	As per EMI Schedule	As per EMI Schedule	
6	Total number of monthly instalments	48	36	60 Months	36 Months	
7	Repayment Start Date	08-07-2019	10-12-2021	04.01.222	06-11-2021	
8	Rate of interest	3.7883% P.A. (PLUS) LIBOR	8.25%	8.50%	14.00%	
9	Additional rate of interest (in case of default)	2%	2%	2%	2%	
10	Security	Office premises- H - 13/14 Everest, 156 Tardo Road, Mumbai 400034	First charge by way of hypothecation in favour of SIDBI on all movables (including current assets) both present and future of the company and all the assets acquired/to be acquired under the project/scheme	As per section Term Loan under CGTME Scheme	UNSECURED	
11	Guarantees	Joint and Several Guarantees by all directors	Joint and Several Guarantees by all directors	CGTMSE	-	
12	Current portion of outstanding amount classified as Current Liability	11.09	7.14	6.50	8.77	
13	Non-Current portion of outstanding amount classified as Non-Current Liability	0.09	4.77	17.88	5.71	
Amount outstanding as on 31-03-2023		11.09	11.91	24.38	14.49	
Sr. No	Particulars	Victoria Hospitals Limited				
		Bank of Baroda (U) Limited	Bank of Baroda (U) Limited	Bank of Baroda (U) Limited		
1	Nature of Loan	Term Loan	Term Loan	Term Loan		
2	Date of Disbursal	29-03-2016	10-01-2017	10-01-2017		
3	Loan Amount	3,500,000 USD	4,30,00,00,000	1,43,60,00,000		
4	Repayment Mode	EMI	EMI	EMI		
5	Amount of each Instalment	63,089 USD (Equivalent to UGX 230,274,850)	10,03,36,951	3,55,54,105		
6	Total number of monthly instalments	72	72	66		
7	Repayment Start Date	01-04-2017	31-12-2017	31-12-2017		
8	Rate of interest	9.00%	20.00%	20.00%		
9	Additional rate of interest (in case of default)	0%	0%	0%		
10	Security	Debenture charge on current assets and fixed assets of the company on both present and future of the company. Legal mortgage of land and building on plot 1495, Kyadondo Block 213 at Bukoto, Kampala LRV 42387, Folio 12 in the name of the Company M/s Victoria Hospital Limited. Legal mortgage of property at Plot 86, Old Kira Road, Bukoto, Kampala in the name of the company M/s Victoria Hospital Limited. Legal Mortgage of two properties (residential flat) being No. 1A 10th Floor, Lotus Block, Nairobi and No. C6, Block C, Nairobi, Kenya all in the name of Mr. Bhasker Kotecha Corporate Guarantee of M/s Midcom (U) Limited	Debenture charge on current assets and fixed assets of the company on both present and future of the company. Legal mortgage of land and building on plot 1495, Kyadondo Block 213 at Bukoto, Kampala LRV 42387, Folio 12 in the name of the Company M/s Victoria Hospital Limited. Legal mortgage of property at Plot 86, Old Kira Road, Bukoto, Kampala in the name of the company M/s Victoria Hospital Limited. Legal Mortgage of two properties (residential flat) being No. 1A 10th Floor, Lotus Block, Nairobi and No. C6, Block C, Nairobi, Kenya all in the name of Mr. Bhasker Kotecha Corporate Guarantee of M/s Midcom (U) Limited	Debenture charge on current assets and fixed assets of the company on both present and future of the company. Legal mortgage of land and building on plot 1495, Kyadondo Block 213 at Bukoto, Kampala LRV 42387, Folio 12 in the name of the Company M/s Victoria Hospital Limited. Legal mortgage of property at Plot 86, Old Kira Road, Bukoto, Kampala in the name of the company M/s Victoria Hospital Limited. Legal Mortgage of two properties (residential flat) being No. 1A 10th Floor, Lotus Block, Nairobi and No. C6, Block C, Nairobi, Kenya all in the name of Mr. Bhasker Kotecha Corporate Guarantee of M/s Midcom (U) Limited		
11	Guarantees	Personal guarantee of directors of the company Dr. Chirag Jagdish Kotecha, Mr Bhasker Kotecha, Mrs. Drashna Kotecha and Mr. Shyam Kotecha.	Personal guarantee of directors of the company Dr. Chirag Jagdish Kotecha, Mr Bhasker Kotecha, Mrs. Drashna Kotecha and Mr. Shyam Kotecha.	Personal guarantee of directors of the company Dr. Chirag Jagdish Kotecha, Mr Bhasker Kotecha, Mrs. Drashna Kotecha and Mr. Shyam Kotecha.		
12	Current portion of outstanding amount classified as Current Liability					
13	Non-Current portion of outstanding amount classified as Non-Current Liability					
Amount outstanding as on 31-03-2023		1,046.96	162.97	125.64		
		1,046.96	162.97	125.64		



Emama

31-03-2023					
Name	Sanction Amount (in lakhs)	Loan Type	Secured/Unsecured	Repayable/EMI	Outstanding Amount as on 31.03.2023 (in Lakhs)
Unihealth Consultancy Limited					
Bank of Baroda	100	Overdraft	Secured against Fixed		79.48
Akshay M Parmar	0		Unsecured	Not Applicable	52.25
Anurag R. Shah	0		Unsecured	Not Applicable	98.64
Prafulla M Parmar	0		Unsecured	Not Applicable	149.75
Mayuri A Parmar	0		Unsecured	Not Applicable	117.25
Mahendra H Parmar	0		Unsecured	Not Applicable	250.4
Vimalchand C Gandhi 9%	0		Unsecured	Not Applicable	20.00
Vimalchand C Gandhi 12%	0		Unsecured	Not Applicable	55.00
Rahul V Gandhi Loan 9%	0		Unsecured	Not Applicable	105.00
Shantilal B Kataria 12%	0		Unsecured	Not Applicable	25.00
Uttamchand Otarmal Ranawa	0		Unsecured	Not Applicable	200.00
Vasanti V Gandhi 12%	0		Unsecured	Not Applicable	32.00
Unihealth Pharmaceutical Private Limited					
Bank of Baroda	62.50	Overdraft	Secured		61.26
Akshay M Parmar	0		Unsecured	Not Applicable	33.30
Anurag R. Shah	0		Unsecured	Not Applicable	126.15
Prafulla M Parmar	0		Unsecured	Not Applicable	37.15
Mayuri A Parmar	0		Unsecured	Not Applicable	32.47
Mahendra H Parmar	0		Unsecured	Not Applicable	9.60
Victoria Hospitals Limited					
Bank of Baroda	410.56	Overdraft	Secured		182.87
Bhasker Kotecha Loan	0		Unsecured	Applicable	454.57
Chirag Kotecha Loan	0		Unsecured	Not Applicable	249.41
Unihealth Consultancy Pvt. Ltd.	0		Unsecured	Not Applicable	726.62
UMC Global Health Limited					
Plenco Industries Limited	0		Unsecured	Not Applicable	148.87
Aditya Bhageria	0		Unsecured	Not Applicable	6.29
Biohealth Limited					
Aryavarta FZE	0		Unsecured	Not Applicable	76.31
Dr Pandey	0		Unsecured	Not Applicable	2.53
Unihealth Consultancy Pvt. Ltd.	0		Unsecured	Not Applicable	80.48
Unihealth Tanzania Limited					
Unihealth Consultancy LTD	0		Unsecured		41.15



Amal

Note S.1 : Terms, Conditions and Other Material Information in respect of Term Loans

(₹ in Lakhs)

31-03-2022		Unhealth Consultancy Limited	
SR. NO.	PARTICULARS	SIDBI LOAN IN FOREIGN CURRENCY	SIDBI LOAN IN INDIAN CURRENCY
1	Nature of Loan	Foreign Currency Term Loan	Mortgage
2	Date of Disbursal	27.07.2018- 1st Tranche amounting to Rs. 30 Lakhs ; 30.08.2018- 2nd and balance tranche amounting to Rs. 30 Lakhs	10-12-2020
3	Loan Amount	INR 60 Lakhs (USD 87273)	21.43 Lakhs
4	Repayment Mode	EMI	EMI
5	Amount of each Instalment	US \$1819 for 47 months & 1 installment for US \$ 1780 in the last month	Principal payment of Rs 0.60 Lakhs for first 35 months & Rs 0.60 Lakhs for last month.
6	Total number of monthly instalments	48	36
7	Repayment Start Date	08-07-2019	10-12-2021
8	Rate of interest	3.7883% P.A. (PLUS) LIBOR	8.25%
9	Additional rate of interest (in case of default)	2%	2%
10	Security	Office premises- H - 13/14 Everest, 150 Tardeo Road, Mumbai 400034	First charge by way of hypothecation in favour of SIDBI on all movables (including current assets) both present and future of the company and all the assets acquired /to be acquired under the project/scheme
11	Guarantees	Joint and Several Guarantees by all directors	Joint and Several Guarantees by all directors
12	Current portion of outstanding amount classified as Current Liability	16.55	7.14
13	Non-Current portion of outstanding amount classified as Non-Current Liability	11.00	11.91
Amount outstanding as on 31-03-2022		27.55	19.05

		Victoria Hospitals Limited		
SR. NO.	PARTICULARS	Bank of Baroda (U) Limited	Bank of Baroda (U) Limited	Bank of Baroda (U) Limited
1	Nature of Loan	Term Loan	Term Loan	Term Loan
2	Date of Disbursal	29-03-2016	10-01-2017	10-01-2017
3	Loan Amount	3,500,000 USD	4,30,80,00,000	1,43,60,00,000
4	Repayment Mode	EMI	EMI	EMI
5	Amount of each Instalment	63,089 USD (Equivalent to UGX 230,274,850)	10,03,36,951	3,55,54,105
6	Total number of monthly instalments	72	72	66
7	Repayment Start Date	01-04-2017	31-12-2017	31-12-2017
8	Rate of interest	9.00%	20.00%	20.00%
9	Additional rate of interest (in case of default)	0%	0%	0%
10	Security	Debenture charge on current assets and fixed assets of the company on both present and future of the company. Legal mortgage of land and building on plot 1495, Kyadondo Block 213 at Bukoto, Kampala LRV 42387, Folio 12 in the name of the Company M/s Victoria Hospital Limited. Legal mortgage of property at Plot 86, Old Kira Road, Bukoto, Kampala in the name of the company M/s Victoria Hospital Limited. Legal Mortgage of two properties (residential flat) being No. 1A 10th Floor, Lotus Block, Nairobi and No. C6, Block C, Nairobi, Kenya all in the name of Mr. Bhasker Kotecha Corporate Guarantee of M/s Midcom (U) Limited	Debenture charge on current assets and fixed assets of the company on both present and future of the company. Legal mortgage of land and building on plot 1495, Kyadondo Block 213 at Bukoto, Kampala LRV 42387, Folio 12 in the name of the Company M/s Victoria Hospital Limited. Legal mortgage of property at Plot 86, Old Kira Road, Bukoto, Kampala in the name of the company M/s Victoria Hospital Limited. Legal Mortgage of two properties (residential flat) being No. 1A 10th Floor, Lotus Block, Nairobi and No. C6, Block C, Nairobi, Kenya all in the name of Mr. Bhasker Kotecha Corporate Guarantee of M/s Midcom (U) Limited	Debenture charge on current assets and fixed assets of the company on both present and future of the company. Legal mortgage of land and building on plot 1495, Kyadondo Block 213 at Bukoto, Kampala LRV 42387, Folio 12 in the name of the company M/s Victoria Hospital Limited. Legal mortgage of property at Plot 85, Old Kira Road, Bukoto, Kampala in the name of the company M/s Victoria Hospital Limited. Legal Mortgage of two properties (residential flat) being No. 1A 10th Floor, Lotus Block, Nairobi and No. C6, Block C, Nairobi, Kenya all in the name of Mr. Bhasker Kotecha Corporate Guarantee of M/s Midcom (U) Limited
11	Guarantees	Personal guarantee of directors of the company Dr. Chirag Jagdish Kotecha, Mr Bhasker Kotecha, Mrs. Drashna Kotecha and Mr. Shyam Kotecha.	Personal guarantee of directors of the company Dr. Chirag Jagdish Kotecha, Mr Bhasker Kotecha, Mrs. Drashna Kotecha and Mr. Shyam Kotecha.	Personal guarantee of directors of the company Dr. Chirag Jagdish Kotecha, Mr Bhasker Kotecha, Mrs. Drashna Kotecha and Mr. Shyam Kotecha.
12	Current portion of outstanding amount classified as Current Liability			
13	Non-Current portion of outstanding amount classified as Non-Current Liability			
Amount outstanding as on 31-03-2022		1,233.90	289.87	134.40
		1,233.90	289.87	134.40



31-03-2022						
Name	Sanction Amount (in lakhs)	Loan Type	Secured/Unsecured	Repayable/EMI		Outstanding Amount as on 31.03.2022 (in Lakhs)
Unihealth Consultancy Limited						
Bank of Baroda	100	Overdraft	Secured against Fixed		20.0%	6.35
Akshay M Parmar	0		Unsecured	Not Applicable	-	17.95
Anurag R Shah	0		Unsecured	Not Applicable	-	67.65
Prafulla M Parmar	0		Unsecured	Not Applicable	-	4.75
Mayuri A Parmar	0		Unsecured	Not Applicable	-	0.50
Mahendra H Parmar	0		Unsecured	Not Applicable	-	25.00
Vimalchand C Gandhi 9%	0		Unsecured	Not Applicable	9.00%	20.00
Vimalchand C Gandhi 12%	0		Unsecured	Not Applicable	12.00%	55.00
Rahul V Gandhi Loan 9%	0		Unsecured	Not Applicable	9.00%	105.00
Rahul V Gandhi Loan 12%	0		Unsecured	Not Applicable	12.00%	25.00
Shantilal B Kataria 12%	0		Unsecured	Not Applicable	12.00%	504.50
Uttamchand Otarmal Ranawa	0		Unsecured	Not Applicable	15.00%	250.00
Vasanti V Gandhi 12%	0		Unsecured	Not Applicable	12.00%	32.00
Victoria Hospitals Limited						
Bank of Baroda	379.50	Overdraft	Secured		20.00%	177.79
Bhasker Kotecha Loan	0		Unsecured	Not Applicable	10.00%	413.44
Chirag Kotecha Loan	0		Unsecured	Not Applicable	10.00%	264.87
Unihealth Consultancy Pvt. Ltd.	0		Unsecured	Not Applicable	10.00%	358.30
Darshana Kotecha	0		Unsecured	Not Applicable	12.75%	15.45
UMC Global Health Limited						
Plenco Industries Limited	0		Unsecured	Not Applicable	-	100.57
Aditya Bhageria	0		Unsecured	Not Applicable	-	7.04
Aryavarta FZE	0		Unsecured	Not Applicable	-	100.53
Dr Pandey	0		Unsecured	Not Applicable	-	2.36
Unihealth Consultancy Pvt. Ltd.	0		Unsecured	Not Applicable	-	37.07



@mlama

Note 5.1 : Terms, Conditions and Other Material Information in respect of Term Loans

31-03-2021		Unihhealth Consultancy Limited		
Sr NO	PARTICULARS	SIDBI LOAN IN FOREIGN CURRENCY	SIDBI LOAN IN INDIAN CURRENCY	SIDBI LOAN IN INDIAN CURRENCY
1	Nature of Loan	Foreign Currency Term Loan	Optionally Convertible Debt (OCD)	Mortgage
2	Date of Disbursal	30-03-2016	23-01-2015	10-12-2020
3	Loan Amount	195.69 Lakhs	100 Lakhs	21.43 Lakhs
4	Repayment Mode	EMI	EMI	EMI
5	Amount of each Instalment	US \$5900 for 50 months and US \$1819 for 24 months	Principal payment of Rs. 1 lakh - for first 20 months & Rs 2 Lakhs for remaining 40 months	Principal payment of Rs.0.60 Lakhs- for first 35 months & Rs. 0.60 Lakhs for last month.
6	Total number of monthly instalments	50	60	36
7	Repayment Start Date	10-10-2016	10-02-2016	10-12-2021
8	Rate of interest	3.75% P.A. (PLUS) LIBOR	14%	8.25%
9	Additional rate of interest (in case of default)	2%	2%	2%
10	Security	Office premises- H - 13/14 Everest, 15 th Tardeo Road, Mumbai 400034	First charge by way of hypothecation in favour of SIDBI on all movables (including current assets) both present and future of the company and all the assets acquired /to be acquired under the project/scheme	First charge by way of hypothecation in favour of SIDBI on all movables (including current assets) both present and future of the company and all the assets acquired /to be acquired under the project/scheme
11	Guarantees	Joint and Several Guarantees by all directors	Joint and Several Guarantees by all directors	Joint and Several Guarantees by all directors
12	Current portion of outstanding amount classified as Current Liability	19.48	6.00	0.00
13	Non-Current portion of outstanding amount classified as Non-Current Liability	26.71	0.00	21.43
Amount outstanding as on 31-03-2021		46.19	6.00	21.43

31-03-2021		Victoria Hospitals Limited		
Sr NO	PARTICULARS	Bank of Baroda (U) Limited	Bank of Baroda (U) Limited	Bank of Baroda (U) Limited
1	Nature of Loan	Term Loan	Term Loan	Term Loan
2	Date of Disbursal	29-03-2016	10-01-2017	10-01-2017
3	Loan Amount	3,500,000 USD	4,30,80,00,000	1,43,60,00,000
4	Repayment Mode	EMI	EMI	EMI
5	Amount of each Instalment	63,089 USD (Equivalent to UGX 230,274,850)	10,03,36,951	3,55,54,105
6	Total number of monthly instalments	72	72	66
7	Repayment Start Date	01-04-2017	31-12-2017	31-12-2017
8	Rate of interest	9.00%	20.00%	20.00%
9	Additional rate of interest (in case of default)	0%	0%	0%
10	Security	Debenture charge on current assets and fixed assets of the company on both present and future of the company. Legal mortgage of land and building on plot 1495, Kyadondo Block 213 at Bukoto, Kampala LRV 42387, Folio 12 in the name of the Company M/s Victoria Hospital Limited. Legal mortgage of property at Plot 86, Old Kira Road, Bukoto, Kampala in the name of the company M/s Victoria Hospital Limited. Legal Mortgage of two properties (residential flat) being No. 1A 10th Floor, Lotus Block, Nairobi and No. C6, Block C, Nairobi, Kenya all in the name of Mr. Bhasker Kotecha Corporate Guarantee of M/s Midcom (U) Limited	Debenture charge on current assets and fixed assets of the company on both present and future of the company. Legal mortgage of land and building on plot 1495, Kyadondo Block 213 at Bukoto, Kampala LRV 42387, Folio 12 in the name of the Company M/s Victoria Hospital Limited. Legal mortgage of property at Plot 86, Old Kira Road, Bukoto, Kampala in the name of the company M/s Victoria Hospital Limited. Legal Mortgage of two properties (residential flat) being No. 1A 10th Floor, Lotus Block, Nairobi and No. C6, Block C, Nairobi, Kenya all in the name of Mr. Bhasker Kotecha Corporate Guarantee of M/s Midcom (U) Limited	Debenture charge on current assets and fixed assets of the company on both present and future of the company. Legal mortgage of land and building on plot 1495, Kyadondo Block 213 at Bukoto, Kampala LRV 42387, Folio 12 in the name of the Company M/s Victoria Hospital Limited. Legal mortgage of property at Plot 86, Old Kira Road, Bukoto, Kampala in the name of the company M/s Victoria Hospital Limited. Legal Mortgage of two properties (residential flat) being No. 1A 10th Floor, Lotus Block, Nairobi and No. C6, Block C, Nairobi, Kenya all in the name of Mr. Bhasker Kotecha Corporate Guarantee of M/s Midcom (U) Limited
11	Guarantees	Personal guarantee of directors of the company Dr. Chirag Jagdish Kotecha, Mr Bhasker Kotecha, Mrs. Drashna Kotecha and Mr. Shyam Kotecha.	Personal guarantee of directors of the company Dr. Chirag Jagdish Kotecha, Mr Bhasker Kotecha, Mrs. Drashna Kotecha and Mr. Shyam Kotecha.	Personal guarantee of directors of the company Dr. Chirag Jagdish Kotecha, Mr Bhasker Kotecha, Mrs. Drashna Kotecha and Mr. Shyam Kotecha.
12	Current portion of outstanding amount classified as Current Liability			
13	Non-Current portion of outstanding amount classified as Non-Current Liability	1,312.52	415.79	141.42
Amount outstanding as on 31-03-2021		1,312.52	415.79	141.42



Amam 4

31-03-2021						
Name	Sanction Amount (in lakhs)	Loan Type	Secured/Unsecured	Repayable/EMI		Outstanding Amount as on 31.03.2021 (in ₹OI Lakhs)
Unihealth Consultancy Limited						
Bank of Baroda	100	Overdraft	Secured against Fixed Deposit		20%	6.41
Akshay M Parmar						22.4
Anurag R Shah	0		Unsecured	Not Applicable		50.06
Prafulla M Parmar	0		Unsecured	Not Applicable		207.35
Mahendra H Parmar	0		Unsecured	Not Applicable		117.45
Vimalchand C Gandhi	0		Unsecured	Not Applicable	9%	20.00
Vimalchand C Gandhi	0		Unsecured	Not Applicable	12%	55.00
Rahul V Gandhi Loan	0		Unsecured	Not Applicable	9%	105.00
Rahul V Gandhi Loan	0		Unsecured	Not Applicable	12%	25.00
Rahul V Gandhi Loan	0		Unsecured	Not Applicable	18%	30.00
Uttamchand Otarmal Ranawa	0		Unsecured	Not Applicable	15%	252.89
Vasanti V Gandhi	0		Unsecured	Not Applicable	12%	32.00
Vasanti V Gandhi	0		Unsecured	Not Applicable	18%	30.00
Victoria Hospitals Limited						
Bank of Baroda	365.83	Overdraft	Secured		20%	147.18
Bhasker Kotecha Loan	0		Unsecured	Not Applicable	10%	368.18
Chirag Kotecha Loan	0		Unsecured	Not Applicable	10%	316.76
Unihealth Consultancy Pvt. Ltd.	0		Unsecured	Not Applicable	10%	314.53
Darshana Kotecha	0		Unsecured	Not Applicable	12.75%	60.55
UMC Global Health Limited						
Plenco Industries Limited	0		Unsecured	Not Applicable	-	111.00
Aditya Bhageria	0		Unsecured	Not Applicable	-	7.43
Biohealth Limited						
Aryavarta FZE	0		Unsecured	Not Applicable	-	96.94
Dr Pandey	0		Unsecured	Not Applicable	-	2.27
Unihealth Consultancy Pvt. Ltd.	0		Unsecured	Not Applicable	-	31.92



Omama

Notes forming part of the Restated Consolidated financial information

Note 6: Restated Consolidated Short Term Borrowings

(₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
	Secured :			
a	Current Maturities of Long Term Debt (Refer Note No 5.1 for Details of Security)	33.51	23.69	25.48
b	Loan Repayable on Demand			
	From Bank of Baroda (Bank overdraft)	323.62	184.14	153.59
	From Other Parties	-	-	-
	Total	357.13	207.83	179.07



Notes forming part of the Restated Consolidated financial information

Note 7 : Restated Consolidated Trade Payables

(₹ in Lakhs)

Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
Due to Micro and Small Enterprises	13.36	0.55	-
Other Payables (Other than Micro and Small Enterprises)	282.63	180.77	155.09
Total	295.99	181.32	155.09

Note 7.1 : Figures For the Reporting Period i.e. 31st March 2023

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Micro and Small Enterprises	12.52	0.84	0.00	-	13.36
Other than Micro and Small Enterprises	264.81	12.26	3.92	1.64	282.63
Dispute dues - Micro and Small Enterprises	-	-	-	-	-
Dispute dues - Others	-	-	-	-	-
Total	277.33	13.10	3.92	1.64	295.99

Note 7.2 : Figures For the Reporting Period i.e. 31st March 2022

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Micro and Small Enterprises	0.55	-	-	-	0.55
Other than Micro and Small Enterprises	166.97	9.31	3.25	1.24	180.77
Dispute dues - Micro and Small Enterprises	-	-	-	-	-
Dispute dues - Others	-	-	-	-	-
Total	167.52	9.31	3.25	1.24	181.32

Note 7.3 : Figures For Reporting Period i.e. 31st March 2021

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Micro and Small Enterprises	-	-	-	-	-
Other than Micro and Small Enterprises	138.10	12.95	1.49	2.55	155.09
Dispute dues - Micro and Small Enterprises	-	-	-	-	-
Dispute dues - Others	-	-	-	-	-
Total	138.10	12.95	1.49	2.55	155.09

In absence of any intimation received from vendors the status of their registration under "The Micro, Small and Medium Enterprises development Act, 2006", the Company is unable to comply with the disclosures required to be made under said Act. Further, the Company declares that there are no unbilled dues.



Notes forming part of the Restated Consolidated financial information

Note 8: Restated Consolidated Other Current Liabilities


(₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
	(i) Statutory dues	31.77	14.00	5.74
	(ii) Advance from customers	0.01	-	-
	(iii) Expenses Payable	383.82	376.53	366.08
	(iv) Security Deposit	12.34	-	-
	(v) Due to associates and related party	127.43	454.34	317.63
	Total	555.37	844.87	689.45

Note 9: Restated Consolidated Short Term Provisions

(₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
a	<u>Provision For Employees Benefit</u>			
	Gratuity	18.56	-	-
b	<u>Others :</u>			
	Provision for Taxation	208.36	59.78	-
	Provision for Expenses	13.33	11.77	12.41
	Total	240.25	71.55	12.41



@mama

Note 10: Restated Consolidated Property, Plant & Equipment and Intangible Assets for the year ended 31st March, 2023

Sr. No	Particulars	Gross Block				Value at the end	Depreciation				Net Block		
		Value at the beginning	Addition on Acquisition of subsidiary wef 15/03/2023	Addition during the year	Deduction during the year		Value at the beginning	Addition on Acquisition of subsidiary wef 15/03/2023	Addition during the year	Deduction during the year	Value at the end	WDV as on 31.03.2023	WDV as on 31.03.2022
I	Tangible Assets												
	Computer	39.41	2.20	1.31	-	42.92	37.02	0.78	2.14	-	39.94	2.98	2.31
	Furniture & Fixtures	132.71	1.50	0.83	-	135.04	96.27	0.43	7.14	-	103.84	31.20	35.06
	Land	301.72	-	-	-	301.72	-	-	-	-	-	301.72	293.33
	Building	2,269.44	-	-	-	2,269.44	502.20	-	90.62	-	592.82	1,676.61	1,719.63
	Leasehold Improvements	27.43	-	-	-	27.43	25.17	-	0.46	-	25.63	1.80	2.18
	Office Equipment	1,288.99	70.02	216.71	-	1,575.72	583.05	11.32	124.86	-	719.23	856.49	681.05
	Electrical Equipment	0.36	-	-	-	0.36	0.34	-	-	-	0.34	0.02	0.02
	Vehicles (Cars)	40.90	-	2.99	4.20	39.69	28.04	-	2.82	4.20	26.66	13.03	12.48
	Plant & Machinery	211.63	-	1.57	-	213.20	129.76	-	21.63	-	151.39	61.81	83.53
													-
	SUB TOTAL (A)	4,312.59	73.72	223.41	4.20	4,605.52	1,401.85	12.53	249.67	4.20	1,659.85	2,945.66	2,829.59
II	Intangible Assets												
	Computer Software	26.47	0.14	-	-	26.61	13.70	0.12	1.97	-	15.79	10.82	11.96
	SUB TOTAL (B)	26.47	0.14	-	-	26.61	13.70	0.12	1.97	-	15.79	10.82	11.96
III	Capital Work-in - Progress												
		51.30	-	-	51.30	-	-	-	-	-	-	-	48.75
	SUB TOTAL (C)	51.30	-	-	51.30	-	-	-	-	-	-	-	48.75
	Total [A + B+C] (Current Year)	4,390.36	73.86	223.41	55.50	4,632.13	1,415.55	12.65	251.64	4.20	1,675.64	2,956.48	2,890.30
	(Previous Year)	4,053.71	-	130.00	-	4,183.71	1,072.19	-	221.22	-	1,293.41	2,890.30	2,821.46

Note-Goodwill on consolidation amounting to Rs 751.46 Lacs is separately disclosed on the face of the restated consolidated Financial Statement and Conversion difference of Rs 206.65 lakhs on the opening gross block and Rs 122.14 lakhs on the opening depreciation in the Fixed Asset schedule is considered in Foreign Currency Translation Reserve.

Note- During FY 2022-23 new subsidiary acquired and shown in the separate column under the head of addition on acquisition. Opening Depreciation Reserve effect on the asset acquired is disclosed separately



Omama

Note 10: Restated Consolidated Property, Plant & Equipment and Intangible Assets for the year ended 31st March, 2022

Sr. No	Particulars	Gross Block				Depreciation				Net Block	
		Value at the beginning	Addition during the year	Deduction during the year	Value at the end	Value at the beginning	Addition during the year	Deduction during the year	Value at the end	WDV as on 31.03.2022	WDV as on 31.03.2021
I	Tangible Assets										
	Furniture & Fixtures	124.47	1.24	-	125.71	82.77	7.88	-	90.65	35.06	40.42
	Computer	36.57	0.77	-	37.34	34.05	0.98	-	35.03	2.31	2.47
	Land	293.33	-	-	293.33	-	-	-	-	293.33	275.13
	Building	2,159.52	-	-	2,159.52	350.59	89.30	-	439.89	1,719.63	1,707.08
	Leasehold Improvements	25.91	-	-	25.91	23.19	0.54	-	23.73	2.18	2.56
	Electrical Equipment	0.36	-	-	0.36	0.34	-	-	0.34	0.02	0.02
	Office Equipment	1,112.31	107.25	-	1,219.56	445.02	93.49	-	538.51	681.05	628.07
	Vehicles (Cars)	39.07	-	-	39.07	23.75	2.84	-	26.59	12.48	14.79
	Plant & Machinery	188.51	20.74	-	209.25	101.59	24.13	-	125.72	83.53	91.67
		-	-	-	-	-	-	-	-	-	-
	SUB TOTAL (A)	3,980.05	130.00	-	4,110.05	1,061.30	219.16	-	1,280.46	2,829.59	2,762.21
II	Intangible Assets										
	Software License	24.91	-	-	24.91	10.89	2.06	-	12.95	11.96	13.53
	SUB TOTAL (B)	24.91	-	-	24.91	10.89	2.06	-	12.95	11.96	13.53
III	Capital Work-in - Progress										
		48.75	-	-	48.75	-	-	-	-	48.75	45.72
	SUB TOTAL (C)	48.75	-	-	48.75	-	-	-	-	48.75	45.72
		-	-	-	-	-	-	-	-	-	-
	Total [A + B+C] (Current Year)	4,053.71	130.00	-	4,183.71	1,072.19	221.22	-	1,293.41	2,890.30	2,821.46
	(Previous Year)	3,759.02	201.39	165.59	3,794.82	754.99	218.52	0.15	973.35	2,821.46	3,012.87

Note-Goodwill on consolidation amounting to Rs 742.92 Lacs is separately disclosed on the face of the restated consolidated Financial Statement and Conversion difference of Rs 258.89 lakhs on the opening gross block and Rs 98.84 lakhs on the opening depreciation in the Fixed Asset schedule is considered in Foreign Currency Translation Reserve.



Omama

Note 10: Restated Consolidated Property, Plant & Equipment and Intangible Assets for the year ended 31st March, 2021

(₹ in Lakhs)

Sr. No	Particulars	Gross Block				Depreciation				Net Block	
		Value at the beginning	Addition during the year	Deduction during the year	Value at the end	Value at the beginning	Addition during the year	Deduction during the year	Value at the end	WDV as on 31.03.2021	WDV as on 31.03.2020
I	Tangible Assets										
	Furniture & Fixtures	112.65	0.56	-	113.21	63.47	9.32	-	72.79	40.42	48.61
	Computer	34.23	0.11	-	34.34	30.72	1.15	-	31.87	2.47	2.86
	Land	275.13			275.13	-	-	-	-	275.13	275.10
	Building	2,043.77			2,043.77	247.06	89.63		336.69	1,707.08	1,796.73
	Leasehold Improvements	24.58	-	-	24.58	21.38	0.64	-	22.02	2.56	3.20
	Electrical Equipment	0.36	-	-	0.36	0.34	-	-	0.34	0.02	0.02
	Office Equipment	813.77	187.37		1,001.14	290.54	82.53		373.07	628.07	652.19
	Vehicles (Cars)	27.21	8.00	0.35	34.86	16.86	3.36	0.15	20.07	14.79	6.99
	Plant and Machinery	193.46	5.35	-	198.81	77.46	29.68	-	107.14	91.67	-
	SUB TOTAL (A)	3,525.16	201.39	0.35	3,726.20	747.83	216.31	0.15	963.99	2,762.21	2,785.70
	Intangible Assets										
	Software License	22.90	-	-	22.90	7.16	2.21	-	9.36	13.53	16.21
	SUB TOTAL (B)	22.90	-	-	22.90	7.16	2.21	-	9.36	13.53	16.21
III	Capital Work-in - Progress	210.96	-	165.24	45.72	-	-	-	-	45.72	210.96
	SUB TOTAL (C)	210.96	-	165.24	45.72	-	-	-	-	45.72	210.96
	Total [A + B+C] (Current Year)	3,759.02	201.39	165.59	3,794.82	754.99	218.52	0.15	973.35	2,821.46	3,012.87
	(Previous Year)	3,766.51	103.92	65.99	3,804.43	572.21	225.20	5.86	791.56	3,012.87	3,195.16

Note-Goodwill on consolidation amounting to Rs 742.92 Laacs is separately disclosed on the face of the restated consolidated Financial Statement and Conversion difference of Rs (45.41) lakhs on the opening gross block and Rs (36.57) lakhs on the opening depreciation in the Fixed Asset schedule is considered in Foreign Currency Translation Reserve.



Omnamay

Notes forming part of the Restated Consolidated financial information

CWIP Aging Schedule

Note 10.1.1 : Figures For the Reporting Period i.e. 31st March 2023 (₹ in Lakhs)

CWIP	Amount in CWIP for a period of				Total
	< 1 year	1-2 years	2-3 years	> 3 years	
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-

Note 10.1.2 : Figures For the Reporting Period i.e. 31st March 2022 (₹ in Lakhs)

CWIP	Amount in CWIP for a period of				Total
	< 1 year	1-2 years	2-3 years	> 3 years	
Projects in progress	-	-	-	48.75	48.75
Projects temporarily suspended	-	-	-	-	-

Note 10.1.3 : Figures For Reporting Period i.e. 31st March 2021 (₹ in Lakhs)

CWIP	Amount in CWIP for a period of				Total
	< 1 year	1-2 years	2-3 years	> 3 years	
Projects in progress	-	-	-	45.72	45.72
Projects temporarily suspended	-	-	-	-	-



Amamya

Notes forming part of the Restated Consolidated financial information

Note 11: Restated Consolidated Non-Current Investments

(₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
a	Investment in Associate			
	Unihealth Uganda Limited (45% Share)	28.71	28.47	36.03
	Total	28.71	28.47	36.03

Note 12: Restated Consolidated Long Term loans and advances

(₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
a	Loans and advances to related parties			
	Unsecured, Considered Good	677.40	335.28	265.12
	Total	677.40	335.28	265.12

Note 13: Restated Consolidated Other Non-Current Assets

(₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
a	Security Deposit			
	Secured, Considered Good	5.85	1.93	1.93
b	Others			
	Interest Receivable	89.14	62.93	56.13
	Total	94.99	64.86	58.06



Umama

Notes forming part of the Restated Consolidated financial information

Note 14 : Restated Consolidated Trade Receivables

(₹ in Lakhs)

Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
Receivables outstanding for less than 6 months			
Secured and Considered Good			
Unsecured and Considered Good			
i) Related Parties			
ii) Others	1,231.41	1,201.22	713.22
Receivables outstanding for more than 6 months			
Secured and Considered Good			
Unsecured and Considered Good			
i) Related Parties			
ii) Others	1,507.95	618.04	705.40
Total	2,739.36	1,819.26	1,418.62

Note 14.1 : Figures For the Reporting Period i.e. 31st March 2023

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	1,231.41	869.77	344.97	60.38	232.83	2,739.36
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-

Note 14.2 : Figures For the Reporting Period i.e. 31st March 2022

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	1,201.22	266.71	96.06	10.83	244.44	1,819.26
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-

Note 14.3 : Figures For Reporting Period i.e. 31 March 2021

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	713.22	302.32	126.96	170.75	105.37	1,418.62
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-



Notes forming part of the Restated Consolidated financial information

Note 15: Restated Consolidated Cash and Cash Equivalents (₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
a	Balances with banks			
	(i) In current accounts	167.67	103.69	24.85
	(ii) In deposit accounts (Fixed Deposit)	-	117.84	9.45
b	Cash on hand	27.71	13.44	170.73
	Total	195.38	234.97	205.03

Note 16: Restated Consolidated Short Term Loans and Advances (₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
a	Loans & Advances to related parties			
	Secured, Considered Good :	-	-	-
	Unsecured, Considered Good :	-	-	-
b	Other Loans and Advances			
	Capital Advances	6.00	7.04	7.00
	Advance to Creditors	2.57	-	-
	Loans and Advance to Employees	40.01	38.98	5.80
	Balance with government authorities	72.60	70.97	54.39
	Prepaid Expenses	57.12	58.76	76.17
	Other		0.78	0.75
	Total	178.30	176.53	144.11

Note 17: Restated Consolidated Other Current Assets (₹ in Lakhs)

Sr. No	Particulars	As at 31st March, 2023	As at 31st March, 2022	As at 31st March, 2021
a	Other Receivables	-	6.33	1.40
	Total	-	6.33	1.40



Amamey

Notes forming part of the Restated Consolidated financial information

Note 18: Restated Consolidated Revenue from Operations

(₹ in Lakhs)

Sr. No	Particulars	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
a	Sale of Goods:	-	138.15	-
b	Sale of Services:			
	Sale of Services (Medical Tourism) Subsidiaries	3,868.00	3,436.64	2,559.11
	Consultancy services	496.72	108.42	61.67
	Export Sales Including Frieght ,Insurance & other Charges	28.12	-	-
		4,392.84	3,545.06	2,620.78
c	Duty Drawback	1.02	-	-
	Total	4,393.86	3,683.21	2,620.78

Note 19: Restated Consolidated Other Income

(₹ in Lakhs)

Sr. No	Particulars	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	Interest income	56.31	35.23	0.54
	Foreign Exchange Gain	121.28	53.30	82.40
	Sundry Balance Written back	8.27	-	104.01
	Profit on sales of Fixed assets	2.37	-	-
	Insurance Claim Received	17.88	16.20	8.24
	Others	3.04	4.75	47.54
	Total	209.15	109.48	242.73

Note 20: Restated Consolidated Employee Benefit Expenses

(₹ in Lakhs)

Sr. No	Particulars	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	Salaries, Bonus, PF & ESIC	645.27	576.47	432.37
	Directors Remuneration	-	6.60	24.00
	Staff welfare expenses	2.46	2.91	3.89
	Total	647.73	585.98	460.26

Note 21: Restated Consolidated Finance Cost

(₹ in Lakhs)

Sr. No	Particulars	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
a	Interest expense on:			
	Term loan	347.06	493.90	73.28
	SIDBI Loan	2.43	3.17	6.01
	Overdraft Facility	39.79	-	9.68
b	Borrowing and other Charges	22.85	21.44	39.88
	Total	412.13	518.51	128.85



Amama

Notes forming part of the Restated Consolidated financial information

Note 22: Restated Consolidated Depreciation & Amortization

(₹ in Lakhs)

Sr. No	Particulars	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	Depreciation	251.62	221.23	218.37
	Total	251.62	221.23	218.37

Note 23: Restated Consolidated Other administrative Expenses

(₹ in Lakhs)

Sr. No	Particulars	Year ended March 31, 2023	Year ended March 31, 2022	Year ended March 31, 2021
	Advertisement Expenses	38.93	50.61	136.76
	Auditors Remuneration	11.58	9.28	6.50
	Clearance, Transport & Freight Charges	23.75	14.80	18.52
	Consultancy Charges	266.84	70.30	19.15
	Fines & Penalties	11.60	1.71	13.16
	Electricity expenses	36.56	37.25	28.02
	Insurance Expenses	20.60	15.97	12.87
	Locum and Specialist Payments	359.65	283.89	245.14
	Medical treatment of Patient	7.99	3.98	14.93
	Membership, Subscription & License Fees	7.99	2.66	6.78
	Miscellaneous Expenses	328.90	235.72	122.37
	Office Expense	21.30	19.35	16.54
	Outsource Services	132.38	123.60	104.11
	Postage and telephone expenses	13.69	14.93	25.64
	Professional and Legal and Government Fees	138.93	30.07	33.07
	Rent, Rates and Taxes	79.49	65.96	25.16
	Repairs and Maintenance Expenses	82.07	79.96	31.94
	Travelling & Visa Expenses	53.27	48.24	26.22
	Total	1,635.52	1,108.28	886.88



Amrany

Notes forming part of the Restated Consolidated financial information

Note-24

Restated Consolidated Related Party Transactions

A) Names of related parties and nature of relationship

i) Key Managerial Personnel(KMP)

Name of Person

Akshay Mahendra Parmar
Anurag Ratan Kumar Shah
Parag Rajnikant Shah

Relation

Managing Director
Director
Whole Time Director & Chief Financial Officer

ii) Entities under common control

Aarzeal Technologies Private Limited
Aryavarta Trading Private Limited
Unity Forgings Private Limited
Unihealth Foundation

iii) Subsidiary Companies

Biohealth Limited
Unihealth Tanzania Limited
Aryavarta FZE
Unihealth Pharmaceuticals Private Limited

iv) Joint Ventures

Victoria Hospitals Limited
UMC Global Health Limited

v) Associate Companies

Unihealth Uganda Limited

vi) Relatives of KMP

Mayuri Akshay Parmar
Mahendra H Parmar
Prafulla Mahendra Parmar
Aryan Akshay Parmar
Dhruv Akshay Parmar
Ratan Kumar Shah
Sangeeta Shah
Shital Parag Shah
Rajnikant Damodardas Shah
Gitaben Rajnikant Shah
Jainil Parag Shah
Dipansh Rajnikant Shah
Ketan Rajnikant Shah
Neha Jaimin Shah
Parag Ratan kumar Shah



P. Maurya

Unihealth Consultancy Limited
CIN : U85100MH2010PLC200491
Notes To Restated Consolidated Financial Statements
Transactions with related parties

(₹ in Lakhs)

Sr. No	Particulars	31-03-2023	31-03-2022	31-03-2021
1	Loan Taken			
	Akshay M parmar	87.76	30.25	45.40
	Anurag Shah	36.65	81.90	63.65
	Mahendra H Parmar	225.40	61.00	18.85
	Mayuri A Parmar	125.65	19.50	4.65
	Prafula M Parmar	145.00	4.75	72.25
2	Rent Service (including taxes)			
	Aarzeal Technologies Pvt Ltd.	1.42	1.42	1.42
	Unihealth Pharmaceuticals Pvt ltd*	2.05	2.05	2.05
3	Loan Repaid			
	Akshay M parmar	53.46	34.70	45.30
	Anurag Shah	5.66	64.31	29.04
	Mahendra H Parmar	-	153.45	48.40
	Mayuri A Parmar	8.90	19.00	4.65
	Prafula M Parmar	-	207.35	7.50
4	Director's Remuneration			
	Parag Shah	6.60	6.60	5.22
	Akshay M Parmar	4.50	-	4.50
5	Loan given			
	Biohealth Limited*	36.02	1.00	18.99
	Victoria Hospitals Limited*	656.44	13.34	-
	Unihealth Tanzania Limited*	41.11		
6	Interest Receivable			
	Biohealth Limited*	7.58	3.97	2.84
	Victoria Hospitals Limited*	81.44	65.50	-
	Unihealth Tanzania Limited	0.12		
7	Export of Goods/Services			
	Victoria Hospitals Limited*	120.82	106.13	1.21
8	Reimbursement of Expenses			
	Unihealth Pharmaceuticals Pvt ltd*	0.02	0.03	-

Balances Outstanding:

Sr. No	Particulars	31-03-2023	31-03-2022	31-03-2021
1	Other Payables			
	Akshay M Parmar	52.25	17.95	22.40
	Anurag Shah	98.64	67.65	50.06
	Mahendra Parmar	250.40	25.00	117.45
	Mayuri A Parmar	117.25	0.50	-
	Prafulla M Parmar	149.75	4.75	207.35
2	Receivables			
	Victoria Hospitals Limited*	25.53	95.52	-
	Biohealth Limited*	19.15	17.65	17.12
3	Other Receivables			
	Victoria Hospitals Limited*	1,451.87	713.99	635.14
	Unihealth Pharmaceuticals Pvt ltd*	-	0.17	-
	Unihealth Tanzania Limited*	41.23	-	-
	Biohealth Limited*	80.64	37.04	32.07

* These transactions are eliminated in the restated consolidated financial information. However, they are disclosed in related party transactions to comply with the requirement of SEBI ICDR guidelines.



Pranay

Notes forming part of the Restated Consolidated financial information

Note-25

Restated Consolidated Accounting Ratios

In accordance with Notification dated March 24, 2021, the Central Government in its Amendment to Schedule III to Companies Act 2013 stated that The Group shall disclose the following ratios which shall indicate the financial performance of The Group. Company is required to give details of significant changes (change of 25% or more as compared to the previous financial year) in sector-specific key financial ratios, as well as any changes in return on net worth.

Sr.No.	Ratios	Numerator	Denominator	31-03-2023*	31-03-2022	% of Change	31-03-2022	31-03-2021	% of Change	31-03-2021	31-03-2020	% of Change
1	Current Ratio (in times)	Current Assets	Current Liabilities	2.29	1.85	24%	1.85	1.85	0%	1.85	1.15	61%
2	Debt Equity Ratio (in times)	Long Tern Debt + Short term debt	Shareholder's Equity*	1.43	2.57	-44%	2.57	3.62	-29%	3.62	7.16	-49%
3	Debt Service coverage ratio (in times)	Earnings available for Debt Services =Net Profit before taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets etc.	Debt Services = Interest & Lease Payments + Principal Repayments	1.03	1.14	-9%	1.14	3.20	-65%	3.20	0.94	242%
4	Return on Equity Ratio (in %)	Profit after Tax	Average Network*	36.19%	29.75%	22%	29.75%	60.42%	-51%	60.42%	-15.10%	500%
5	Inventory Turnover Ratio (in times)	COGS	Average Inventory	3.73	5.15	-28%	5.15	5.63	-9%	5.63	6.82	-17%
6	Trade Receivables turnover ratio (in times)	Net Credit Sales	Average trade receivables	1.93	2.28	-15%	2.28	1.96	16%	1.96	2.18	-10%
7	Trade payables turnover ratio (in times)	Total Credit Purchases	Average Trade Payables	2.93	5.18	-43%	5.18	1.91	171%	1.91	0.83	130%
8	Net Capital Turnover Ratio (in times)	Sales	Working capital (CA-CL)	2.34	3.31	-29%	3.31	2.98	11%	2.98	8.37	-64%
9	Net profit ratio (in %)	Net Profit	Sales	17.48%	10.37%	69%	10.37%	19.11%	-46%	19.11%	-3.81%	602%
10	Return on Capital employed (in %)	Profit before tax and finance costs	Capital employed = Total Assets - Current Liabilities	20.99%	20.08%	5%	20.08%	14.08%	43%	14.08%	2.05%	587%
11	Return on investment	Net Income	Cost of Investment	NA	NA	NA	NA	NA	NA	NA	NA	NA

* Equity excluding Minority Interest

Detailed explanation for significant changes in sector-specific key financial ratios and changes in Return on Net Worth:

Sr.No.	Ratios	% of Change 31-03-2023	Reason for Variance	% of Change 31-03-2022	Reason for Variance	% of Change 31-03-2021	Reason for Variance
1	Current Ratio (in times)	24%	NA	0%	NA	61%	Due to Increase in Net Working Capital
2	Debt Equity Ratio (in times)	-44%	Due to Increase in Earnings added to Shareholders' Equity	-29%	Due to Increase in Earnings added to Shareholders' Equity	-49%	Due to Increase in Earnings added to Shareholders' Equity
3	Debt Service coverage ratio (in times)	-9%	NA	-65%	Due to Increase in Borrowings and Interest Cost	242%	Due to Increase in Earning before interest and tax
4	Return on Equity Ratio (in %)	22%	NA	-51%	Due to decrease in Profit After Tax as compared to PY 2021	500%	Due to Increase in Profit After Tax as compared to PY 2020
5	Inventory Turnover Ratio (in times)	-28%	Due to Increase in the Inventory holding	-9%	NA	-17%	Due to Increase in the Inventory holding
6	Trade Receivables turnover ratio (in times)	-15%	NA	16%	Due to Reduction in Trade Receivables	-10%	Due to Increase in Trade Receivables
7	Trade payables turnover ratio (in times)	-43%	Due to Increase in Trade Payables	171%	Due to Reduction in Trade Payables	130%	Due to Reduction in Trade Payables
8	Net Capital Turnover Ratio (in times)	-29%	Due to Increase in Net Working Capital	11%	NA	-64%	Due to Increase in Net Working Capital
9	Net profit ratio (in %)	69%	Due to Increase in Profit After Tax as compared to PY 2022	-46%	Due to decrease in Profit After Tax as compared to PY 2021	602%	Due to Increase in Profit After Tax as compared to PY 2020
10	Return on Capital employed (in %)	5%	NA	43%	Due to Increase in Earning before interest and tax	587%	Due to Increase in Earning before interest and tax
11	Return on Investment	NA	NA	NA	NA	NA	NA



Notes forming part of the Restated Consolidated financial information

Note-26

Restated Contingent Liabilities and Commitments:

(₹ in Lakhs)

Particulars	31st March, 2023	31st March, 2022	31st March, 2021
(i) Contingent Liabilities			
Details of Claims against the Company not acknowledged as Debt include:			
(a) Demands Raised by Income Tax Department in respect of:			
FY 2012-13	0.22	0.22	0.22
FY 2015-16	0.09	0.09	0.09
FY 2016-17	454.35	442.61	442.61
FY 2017-18	394.41	384.66	384.66
(b) suit filed by the patients against the Company	38.98	-	-
(c) supplier dues	1.82	1.82	1.82
(ii) Commitments	-	-	-
Total	889.87	829.40	829.40


Note-27

Restated Statement of EPS

(₹ in Lakhs)

Particular	31st March, 2023	31st March, 2022	31st March, 2021
Profit for the year (A)	768.00	382.02	500.89
Weighted number of equity shares outstanding (B)	13,42,136	13,41,875	13,41,875
Face Value per Equity Shares in Rs	10.00	10.00	10.00
Basic EPS (in Rs)*	6.94	3.45	4.53
Diluted EPS (in Rs.)*	6.94	3.45	4.53

*a) 97,26,458 no. of Bonus Shares in the ratio of 7:1, based on the shareholding as on 31/03/2023, issued by the company post restated consolidated Financial information period but before filing of RHP, is considered for the computation of Basic & Diluted EPS and in line of AS - 20. For the purpose of rational comparison, the Basic & Diluted EPS is computed, as if, the bonus shares are issued as on the 01st April of first year of restated Consolidated financial Information.



Notes forming part of the Restated Consolidated financial information

Note-28

Restated Statement of Capitalisation

(₹ in Lakhs)

Particulars	Pre Issue as at March 31, 2023	Post Issue
Borrowings		
Short- term	323.62	[.]
Long- term (including current maturities) (A)	3,603.05	[.]
Total Borrowings (B)	3,926.67	[.]
Shareholder's fund		
Share capital	138.95	[.]
Reserve and surplus, as restated	2,612.83	[.]
Total Shareholder's fund (C)	2,751.78	[.]
Long- term borrowings / equity ratio {(A)/(C)}	1.31	[.]
Total borrowings / equity ratio {(B)/(C)}	1.43	[.]



Amama

Notes forming part of the Restated Consolidated financial information

Note 29

Restated Reconciliation of Profit and Network:

Restated Reconciliation of Profit:

The reconciliation of Profit/(Loss) after tax, before Minority Interest as per audited financial statements and the Profit/(Loss) after tax, before Minority Interest as per Restated Accounts is presented below. This summarizes the results of restatements made in the audited accounts for the respective years and its impact on the profit & losses of the company.

(₹ in Lakhs)			
Particulars	31.03.2023	31.03.2022	31.03.2021
Profit/(Loss) after tax, before Minority Interest as per Audited Financial Statements	765.67	379.25	493.96
Adjustments for:			
Increase / (Decrease) in Income / Expenses (Note "a")	-	-	1.07
Profit/(Loss) after tax, before Minority Interest as per Restated Consolidated Financial Statements	765.67	379.25	495.03

Notes:

a) The Amount relating to the Income / Expenses have been adjusted in the year and the head to which the same relates to.

Reconciliation of Restated Network:

The reconciliation of Network as per audited results and the Network as per Restated Accounts is presented below. This summarizes the results of restatements made in the audited accounts for the respective years and its impact on the Network of the company.

(₹ in Lakhs)			
Particulars	31.03.2023	31.03.2022	31.03.2021
Network as per Audited Financial Statements	2,751.78	1,503.02	1,136.63
Adjustments for:			
Increase / Decrease in Income / Expenses as per table "Reconcili	-	(56.18)	(56.18)
Restatement - Minority Interest (Note "a")	-	29.02	18.69
Restatement - Share of Profit/(Loss) from Associate (Note "b")	-	(5.26)	0.82
Restatement - Foreign Currency Translation Reserve (Note "c")	-	8.57	(29.60)
Network as per Restated Consolidated Financial Statements	2,751.78	1,479.17	1,070.36

Notes:

a) Minority interest has been restated in order to give effect of restatement In profit / (loss) of subsidiary.

b) Share of Profit/Loss from Associate has been restated in order to give effect of alignment of financial year of Associate with financial year of Holding Company.

c) In order to ensure consistency with parent's policy that assets and liabilities (other than non-monetary items) are translated at the exchange rate prevailing on the Balance Sheet date. Thus, the resulting difference of exchange differences arising out of these translations are charged to the Foreign currency translation reserve.



Notes forming part of the Restated Consolidated financial information

Note 30

Restated Segment Reporting

A. Business Segments:

Based on the guiding principles given in Accounting Standard 17 (AS - 17) on Segment Reporting issued by ICAI, the Company has only one reportable Business Segment, which is Healthcare Services and Trading in its related products. Accordingly, the figures appearing in these financial statements relate to the Company's single Business Segment.

B. Geographical Segments:

The Group has identified geographic segments as its primary segment. Geographical revenue is allocated based on the location of the customer. Geographic segments of the Group are India, Uganda, Tanzania, Nigeria and UAE.

(₹ in Lakhs)

Geographic Segment	31-03-2023		31-03-2022		31-03-2021	
	Segment Revenue	Segment Assets	Segment Revenue	Segment Assets	Segment Revenue	Segment Assets
India	162.56	2,035.25	108.41	1,485.40	62.06	1,298.61
Uganda	3,013.77	4,731.65	2,780.91	4,007.94	1,985.17	3,584.68
Tanzania	102.51	247.28	122.70	268.42	165.03	192.09
Nigeria	751.72	528.36	602.11	434.99	408.52	314.22
UAE	363.30	290.78	69.08	281.90	0.00	449.27



Omiana

Notes forming part of the Restated Consolidated financial information

Note 31

Material events occurring after the date of Restated Consolidated Statement of Assets and Liabilities

In line with Accounting Standard 4, following non adjusted material events occurred after the period of restated consolidated Financial Information

- 1 Pursuant to a resolution passed by Board of Directors of the company on January 4, 2023, the Company has approved to become first subscriber to Memorandum of Association of UHS Oncology Private Limited by subscribing to its Memorandum of Association (MOA) for 3,333 no. of equity shares in the incorporation on 16th January, 2023, amounting to Rs. 33,333. Payment for the said subscription was effected on May 18, 2023.
- 2 Pursuant to a resolution passed by Board of Directors of the company on 27th April, 2023 and a resolution passed by the Shareholders in the EGM held on 29th April, 2023 the company has approved issuance of 97,26,458 no. of Equity Shares of Rs. 10 each as Bonus Shares in the ratio of 7:1 out of Security Premium Reserve Account.

Note 32

Material Adjustment to Restated Consolidated Financial Information [As per the SEBI (ICDR) Regulation]

Appropriate adjustment have been made in the restated financial information, wherever required, by reclassification of the corresponding item of income, expenses, assets and liabilities, in order to bring them in line with the groupings as per audited financial of the company for all the years and the requirements of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulation 2018.




Omama

Notes forming part of the Restated Consolidated financial information

Note 33: Additional Notes as per Schedule III

Additional Regulatory Information as required by paragraph 2 of the General instruction for preparation of CFS as per Schedule III to the Companies Act, 2013

- 1 No proceedings have been initiated or pending against Company for holding any Benami Property under Prohibitions of Benami Transactions Act,1988 (Earlier titled as Benami Transactions (Prohibitions) Act,1988.
- 2 The Company has borrowings from Banks or Financial Institutions on the basis of Fixed Deposits in india. However, no quarterly return or statement is required to be filed with the bank or Financial Institution. In case of foreign Joint Venture, borrowing is secured by current Assets but no quarterly return is prescribed thereat.
- 3 The Company has not been declared as willful defaulter.
- 4 The Company has no transaction with Companies which are stuck off under section 248 of the Companies Act,2013 or under section 560 of Companies Act,1956.
- 5 No charges are pending for registration or satisfaction with the Registrar of Companies (ROC).
- 6 The Company is in compliance with the no. of layers as prescribed under clause (87) of section 2 of The Companies Act, 2013 read with the Companies (Restriction on Number of Layers) Rules, 2017.
- 7 During the Consolidated restated Financial Information period, no Scheme of Arrangement has been formulated by the Company/pending with competent authority.
- 8 The Company does not have transaction not recorded in the books of accounts that has been surrendered or disclosed as income during the Consolidated restated Financial Information period in the Tax Assessments under the Income Tax Act, 1961.
- 9 The Company has not traded or invested in Crypto Currency or Virtual Currency during the Consolidated restated Financial Information period.
- 10 The company has not revalued Property, Plant and Equipment.
- 11 Immovable properties are in the name of the company
- 12 The Company has not advanced or loaned or invested funds, with any understanding, to any other person(s) or entity(ies), including foreign entities (Intermediaries) that the Intermediary shall:
 - a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - (b) Provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- 13 The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (b) Provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.



Omama

Notes forming part of the Restated Consolidated financial information

Note-34 Other Restated Financial Information

Metric	As of and for the Financial Year		
	31-03-2023	31-03-2022	31-03-2021
Restated Profit/(Loss) for the period/year (A) (₹ In Lakhs)	768.00	382.02	500.89
Weighted Average Number of equity shares in calculating Basic EPS (B)	1,10,68,594	1,10,68,333	1,10,68,333
Weighted Average Number of equity shares in calculating Diluted EPS (C)	1,10,68,594	1,10,68,333	1,10,68,333
Number of Shares Outstanding for Basic EPS (C1) (For NAV)	1,11,15,952	1,10,68,333	1,10,68,333
Number of Shares Outstanding for Diluted EPS (C2) (For NAV)	1,11,15,952	1,10,68,333	1,10,68,333
Basic Earnings Per Share (In ₹) (D = A/B)*	6.94	3.45	4.53
Diluted Earnings Per Share (In ₹) (E = A/C)*	6.94	3.45	4.53
Total Equity (F) (₹ In Lakhs)	2,751.78	1,479.17	1,070.36
Return on Equity (G = A/F*100)	27.91%	25.83%	46.80%
Net Asset Value Per Equity Share (basic) (H = F/C1) (In ₹)	24.76	13.36	9.67
Net Asset Value Per Equity Share (Diluted) (I = F/C2) (In ₹)	24.76	13.36	9.67
EBITDA (₹ In Lakhs) (J)	1,591.53	1,260.09	894.62
Revenue from Operations (₹ In Lakhs) (K)	4,393.86	3,683.21	2,620.78
EBITDA Margin (%) (L = J/K*100)	36.22%	34.21%	34.14%
RONW (M=A/F*100)	27.91%	25.83%	46.80%

Note-

*a) 97,26,458 no. of Bonus Shares in the ratio of 7:1, based on the shareholding as on 31/03/2023, issued by the company post restated consolidated Financial information period but before filing of RHP, is considered for the computation of Basic & Diluted EPS and in line of AS - 20. For the purpose of rational comparison, the Basic & Diluted EPS is computed, as if, the bonus shares are issued as on the 01st April of first year of restated Consolidated financial Information.

Note 35

Previous year figures have been regrouped/rearranged wherever considered necessary.

G P Kapadia & Co,
Chartered Accountants
Firm registration No: 104768W

Atul B Desai
Partner
Membership No. 030850
Mumbai
Date- 21st August, 2023



For and on behalf of the Board of Directors
Unihealth Consultancy Limited

Akshay M Parmar
Managing Director
DIN:01533004

Prajakta Suresh Bhor
Company Secretary
Membership No.: A55171



Anurag Shah
Director
DIN:02544806

Parag Shah
Whole Time Director
& Chief Financial Officer
DIN: 07773426